Regimens of first-line chemotherapy	Overall	MTB or MK infection

		(+)	(–)

	N = 30	N = 7	N = 23

Intensive regimens	26	6	20

 FOLFOX	8	2	6

 FOLFOX + Bmab	6	1	5

 FOLFIRI	6	1	5

 FOLFOX + Pmab/Cmab	2	2	0

 FOLFIRI + Pmab/Cmab	2	0	2

 FOLFIRI + Bmab	1	0	1

 XELOX	1	0	1

Non-intensive regimens	4	1	3

 UFT/LV	1	1	0

 S-1	2	0	2

 Capecitabine	1	0	1

Response rate (%)	40.0	28.6	43.5

 CR	1	1	0

 PR	11	1	10

 SD	10	2	8

 PD	7	3	4

 NE	1	0	1


Activity against the Isolates

Antibiotics	Resistance Prevalence (%)	MIC (mg L−1)

Range	50%	90%

Ampicillin (AMP)	100.0	64 to ≥1024	1024	1024

Amoxicillin (AMO)	100.0	1 to ≥1024	1024	1024

Streptomycin Sulfate (STR)	92.3	1 to ≥1024	128	512

Trimethoprim (TRI)	98.0	8 to ≥1024	1024	1024

Chloramphenicol (CHL)	100.0	256 to ≥1024	1024	1024

Sulfonamide (SUL)	100.0	512 to ≥1024	1024	1024

Tetracycline (TET)	90.6	2 to ≥512	128	256

Oxytetracycline (OXY)	90.6	1 to ≥1024	256	512

Nalidixic Acid (NAL)	73.6	1 to ≥1024	512	1024

Erythromycin (ERY)	92.5	4 to ≥1024	128	512

Spiramycin (SPIRA)	90.6	2 to ≥1024	512	1024

Kanamycin (KAN)	54.7	1 to ≥1024	128	1024


Study	Year	N	Criteria	Treatment	Findings

Hu et al. [6]	2006	84	Solitary brain metastasis	SRS or surgery	Stage I intrathoracic patients had better OS outcomes than stage III

Bonnette et al. [7]	2001	108	Brain metastasis (98 with solitary)	Surgery	Adenocarcinoma, T stage, complete resection with better outcomes

Rodrigues et al. [8]	2011	66	≤6 intracranial lesions	Image-guided SIB RT	Presence of systemic disease, lower performance status correlated with decreased OS

Iwasaki et al. [9]	2004	41	Solitary brain metastasis	Resection of primary site and brain metastasis	Risk score criteria for improved OS:adenocarcinoma, node-negative, normal CEA level

Mussi et al. [10]	1996	52	Solitary brain metastasis	Resection of primary site and brain metastasis	No status, lobectomy associated with decreased OS. 5-year OS in patients with synchronous/metachronous lesions 6.6/19%, respectively

Machiarini et al.[11]	1991	37	Solitary brain metastasis. Synchronous (<1 month) and metachronous included.	Resection of primary site and brain metastasis	Most frequent site of first recurrence was ipsilateral thorax (n = 14) and brain (n = 6). The receipt of adjuvant chemotherapy was strongest predictor of disease-free interval

Wronski et al. [12]	1995	231	Single (87%) or multiple (13%) metastatic intracranial lesions	Resection	Female gender, complete location, infratentorial location, no systemic metastases, age < 60 years associated with improved OS


	Diabetic (N = 8)	Non-diabetic (N = 60)	p value

Days till admission, median (range)	4 (0–49)	15 (0–49)	0.367

Referral, No (%)			0.088

 Admission to hospital > 1 day	7 (87.5)	49 (81.7)

 Admission to hospital refused by patient	1 (12.5)	0 (0.0)

 Day treatment	0 (0.0)	11 (18.3)

Additional hospitalization, No (%)a	1 (12.5)	8 (13.6)	1.000

Median length of stay, days (range)	20 (4–41)	5 (1–30)	0.025

Complications, No (%)b	5 (62.5)	10 (17.5)	0.013

Treatment, No (%)a			0.549

 Graft	7 (87.5)	54 (91.5)

 Necrotectomy only	0 (0.0)	1 (1.7)

 Conservative	1 (12.5)	4 (6.8)

Additional surgery, No (%)a	2 (25.0)	4 (6.8)	0.147

Complete epithelialization after first treatment, No (%)c	6 (85.7)	45 (83.3)	1.000

Days till complete epithelialization, median (range)	44 (17–93)	31 (10–192)	0.660

Take graft, No (%)d

			0.365

 Good	6 (75.0)	48 (85.7)

 Moderate	1 (12.5)	4 (7.1)

 Inapplicable	1 (12.5)	4 (7.1)


Method	Phen. allowed a	Input values b	Kc	Link

Ref-based	Any	Beta	N/A	http://people.oregonstate.edu/~housemae/software/TutorialLondon2014

				http://bioconductor.org/packages/release/bioc/html/minfi.html

Ref-free	Any	Beta	Estimated	http://cran.r-project.org/web/packages/RefFreeEWAS/index.html

SVA	Any	Beta or logit(beta)	Estimated	http://bioconductor.org/packages/release/bioc/html/sva.html

ISVA	Continuous	Beta or logit(beta)	Estimated	http://cran.r-project.org/web/packages/isva/index.html

EWASher	Binary	Beta	Estimated	http://research.microsoft.com/en-us/downloads/472fe637-7cb9-47d4-a0df-37118760ccd1

CellCDec	Not used	Beta	Input	https://github.com/jameswagner/CellCDec

Deconf	Not used	Beta or logit(beta)	Input	http://web.cbio.uct.ac.za/~renaud/CRAN

RUV	Any	Beta or logit(beta)	Estimated	https://cran.r-project.org/web/packages/ruv/index.html


Material	Fixation method	Approximate global size (mm)	Maximum deviation factor	Minimum size factor	Number of elements

Cement	—	2.0	0.02	0.1	107556

Femoral prosthesis	—	1.5	0.05	0.1	631470

Femur	Cemented	2.0	0.05	0.1	761218

Noncemented	2.0	0.05	0.1	792849

Total number of elements	Cemented	—	—	—	1500244

Noncemented	—	—	—	1424319


Facies type	Model	Nugget	Partial sill	Range (m)

Sand flats	Exponential	0.103	0.223	3015

Mixed flats	Spherical	0.186	0.065	1029

Mud flats	Spherical	0.099	0.295	7575


GCA Classification Criteria

(1) Age at onset ≥50 years

(2) A new headache

(3) Temporal artery abnormality such as tenderness to palpation or decreased pulsation

(4) Erythrocyte sedimentation rate ≥50 mm/h

(5) Abnormal artery biopsy showing vasculitis with mononuclear cell or granulomatous inflammation, usually with giant cells


Items	Issues

Model units	• Headcounts do not reflect variation in effective workforce.• FTE measured in working hours can translate into a variable effective workforce.• FTE defined in reference to the most active physician category makes the assumption that the activity level in that category is relevant.

Data quality	• Routine data are useful, but provide generally limited information.• Various data sources coexist, with inconsistencies between them.• Qualitative data for in-depth understanding of trends is often lacking.

Categories of resources	• Computation of human resources requirements by specialty obviates professional interactions and skill mix.• Assessing skill-mix requirements is a complex task and documentation is often lacking.

Supply parameters	• Information other than age, sex and services volume is often unavailable.• Productivity is sensitive to the working and societal environment and is rapidly evolving.

Demand parameters	• Assessing the impact of new technologies, emerging pathologies and demographic changes requires a large quantity of data and expertise that are often unavailable.• Level and mode of health care utilization are sensitive to the environment and are rapidly evolving.

Modeling	• Deterministic models are likely to generate inaccuracies without providing a means to evaluate them.• Regression modeling with stochastic simulation can be innovative in the HRH field but background is lacking• Regular updating of data is paramount but resource-consuming.


Variable	N	%

Age in years (n = 1533)

 15–19	15	1

 20–29	455	29.7

 30–39	710	46.3

 40–49	242	15.8

 50 and above	111	7.2

Sex (n = 1549)

 Female	1333	86.1

Caregiver relationship to a child (n = 1546)

 Mother	1257	81.3

 Father	130	8.4

 Relative	159	10.3

Marital status (n = 1546)

 Married	1210	78.3

 Single, separated or divorced	179	11.5

 Widow or widower	157	10.2

Education level (n = 1546)

 None or informal	170	11.0

 Primary	285	18.4

 Secondary	703	45.5

 Postsecondary Diploma and above	388	25.1

Employment status (n = 1532)

 None	326	21.3

 Employed in informal sector	988	64.5

 Employed in formal sector	218	14.2

Income status (n = 1474)

 <N18,000	914	62.0

 N18,000–50,000	427	29.0

 N51,000–100,000	105	7.1

 >N100,000	28	1.9


Category	Subcategory	Cases	Monocytes(/mm3)	P value

			<545	≥545

Gender	Male	310	115	195	0.102

	Female	41	20	21

Age	<50 years	268	102	166	0.418

	≥50 years	83	33	50

HBsAg	Negative	49	14	35	0.083

	Positive	302	121	181

AFP(ng/ml)	<200	161	61	100	0.463

	≥200	190	74	116

Edmonson grading	I-II	271	107	164	0.278

III-IV	80	28	52

Tumor size	<5 cm	70	35	35	0.019

≥5 cm	281	100	181

Surgical margin	<1 cm	122	44	78	0.289

≥1 cm	229	91	138

Liver cirrhosis	Absent	82	29	53	0.3

Present	269	106	163

PVTT	Absent	278	108	170	0.44

	Present	73	27	46

Capsulation	Capsulated	224	92	132	0.111

Non-caspulated	127	43	84

Tumor number	Single	276	107	169	0.465

Multiple	75	28	47

Macrovascular invasion	Absent	261	102	159	0.391

	Present	90	33	57


Collection time	AKI (renal replacement)	Mean	Std	p-value

T1 preoperative	No	1,0	,27	0,06

Yes	1,24	,43

T2 start CBP	No	,80	,21	0,07

Yes	,96	,31

T3 20 minutes after CBP start	No	,89	,21	0,06

Yes	1,05	,32

T4 OP-end	No	1,00	,26	0,03

Yes	1,22	,30

T5 24 h postoperative	No	1,26	,52	0,002

Yes	1,93	,47

T6 discharge(max. day 6)	No	1,28	,40	0,001

 	Yes	2,09	,57


Model	Standardized coefficients	t	Sig.	95.0 % confidence interval for B

Beta	Lower bound	Upper bound

(Constant)		−12.353	<0.001	−1.67	−1.21

Educational level of mothers	0.08	3.273	0.001	0.06	0.23

Appropriate complementary feeding score	0.04	1.927	0.05	−0.002	0.27

Diarrhoeal infection	0.10	4.499	<0.001	0.14	0.35

Gender of child	0.05	2.209	0.03	0.012	0.209


Phytochemical	Name of the tests	Observed changes	Result

Alkaloids	Mayer's test	Creamy white precipitate	−

Hager's test	Yellow crystalline precipitate	 +

Wagner's test	Brown or deep brown precipitate 	−

Dragendorff's test	Orange or orange-red precipitate	−

Tannic acid test	Buff color precipitate	−

Carbohydrates	Molisch's test	A red or reddish violet ring is formed at the junction of two layers and on shaking a dark purple solution is formed	+

Barfoed's test (general test for monosaccharides)	Red precipitate	−

Fehling's test	A red or brick-red precipitate	−

Benedict's test	 	+

Test for combined reducing sugar	A brick-red precipitate	−

Glycosides	General test	Yellow color	−

Bromine water test 	yellow precipitate	+

Test for glucoside	Production of brick-red precipitation (carried out with the hydrolyzed extract)	−

Flavonoids	Alkaline reagent test	Red color	+/−

Shinoda test (magnesium hydrochloride reduction test)	Green to blue color	+

Zinc hydrochloride reduction test	Red color after few minutes 	−

Saponins	Frothing test	Formation of stable foam	+

Steroids	Libermann-Burchard's test	Greenish color	−

Tannins	Lead acetate test	A yellow or red precipitate	 +

Ferric chloride test	Blue green color	−

Alkaline reagent test	Yellow to red precipitate	+

Terpenoids	Salkowski test	Yellow color appears at the lower layer 	−


Strength of interaction	Definition

Strong	A strong inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a substrate for that CYP by equal to or more than 5-fold (or >80% decrease in clearance)

Moderate	A moderate inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 5-fold but equal to or more than 2-fold (or 50%–80% decrease in clearance)

Weak	A weak inhibitor for a specific CYP is defined as an inhibitor that increases the AUC of a sensitive substrate for that CYP by less than 2-fold but equal to or more than 1.25-fold (or 20%–50% decrease in clearance)


Annotation category	Resource	Comments

Genomic	GENCODE	Variant classification and mapping to gene

	Human DNA Repair Genes	Curated list from [40]

Protein	UniProt	Protein-specific annotation

	dbNSFP	Conservation and prediction scores

Cancer variant	COSMIC	Catalogue of Somatic Mutations in Cancer

Non-cancer variant	1000 Genomes Project	Germline SNVs


Country	Sample Size SpA	Sample Size (Control)	Prevalence in Population	Prevalence in SpA	Prevalence in AS	OR AS/GP [95% CI]	Reference

Algeria	129 AS (ESSG and NY)	76 healthy blood donors	4%		69%	54.14 [16.09–182.18]	[17]

Egypt		380 normal individuals	4.7%				[18]

Egypt	75 SpA (ESSG) including 34 AS			58.7%			[19]

Egypt		100 healthy controls	1%				[20]

Iraq	25 AS		2.1%		84%		[21]

Iran	60 AS	430 healthy blood donors	3.95%		66.67%	48.59 [23.57–100.17]	[22]

Iran	119 AS				68.91%		[23]

Iran	98 AS (NY)				73.4%		[24]

Israel	38 AS	456 normal individuals	3%		79%		[25]

Jordan	22 AS (NY)				75%		[26]

Jordan / Qatar	129 AS	2579 healthy individuals	2.4%		72.22%	104.87 [66.21–166.11]	[12]

Kuwait	58 SpA (27 AS)			69.43%	82.56%		[27]

Kuwait	35 SpA + AS patients	544 controls	4%	25.7%		8.21 [3.44–19.60]	[28]

Lebanon	105 SpA (ESSG)24 AS (NY)	841 Rheumatolgy patients	1.44%	13.85%	26.32%	24.46 [7.78–68.19]	[29]

Morocco	46 AS + coxitis	183 healthy controls	6.16%		58.70%	22.09 [9.48–51.49]	[30]

Morocco	49 SpA (Amor and ESSG)				67%		[31]

Oman		321 healthy	0.3%				[32]

Qatar	119 AS (NY)				74%		[33]

Saudi Arabia	12 AS				66.67%		[34]

Syria	50 AS (NY)	217 healthy controls	1.4%		60%	105.64 [29.98–381.87]	[35]

Tunisia	365 AS and/or BD	124 controls	3.2%		42.9%		[36]

Tunisia	100 AS (NY)	100 healthy controls	3%		62%	52.75 [15.61–178.31]	[37]

Tunisia	50 AS (Amor / ESSG)				69%		[38]

Turkey	112 AS (NY)	55 controls	2.8–6.8%		70%	29.82 [9.99–89.05]	[39]

Turkey	216 AS (67 analyzed)				91%		[40]

UAE		760 healthy	6.4%				[41]

UAE	17 AS				56%		[42]


Covariate	Relative risk	95 % CI	p value

p62	0.764	NS	0.619

Histological grading	1.239	NS	0.392

Lymph node metastases	0.794	NS	0.510

Tumour stage	1.647	NS	0.141

Distant metastases	3.176	1.453-6.940	0.004


Food	GI

Gluten-free bread	230

Gluten-free pasta	255

Quinoa	186


Laccase Isoform	Experimental Affinity Rank 1	HINT Score

Beta	1	430

Gamma	2	206

Delta	3	104


Isolates	Body site	spa type	SCCmec	STa	PFTb

27 N	nasal	t002	II	ST105	A1

08 N	nasal	t311	II	ST105	B1

P65N	nasal	t002	II	ST105	C

98I	groin	t14789	IVa	ST1176	D1

62 N	nasal	t149	I	ST5	E1

P32N	nasal	t37	III	ST239	F1

78 N	nasal	t110	I	ST105	G

111 N	nasal	t002	II	ST105	H

59 N	nasal	t149	IVa	ST1510	I


Features 	 DNA configurations

 A 	 B 	 Z

Helix orientation 	 Right-handed 	Right-handed 	Left-handed

DNA diameter 	 2.55 	 2.37 	 1.84

bp diameter 	 1.0 	1.0 	 0.6

bp axial step 	 0.23 	 0.33 	 0.38

Helix pitch 	 2.46 	 3.2 	 3.0

bp/helix turn 	 10.7 	 10 	 12

bp/nucleosome 	 286 	 198 	 172

Helix axial shift 	 0.76 	 1.2 	 0.77

Target angular aperture 	 87°	 73°	 60°

Target height 	 0.119 	 0.183 	 0.249

Total number of bp 	7.72 × 108	5.35 × 108	4.64 × 108

Target volume (nm3) 	 0.12 	 0.13 	 0.10


Kano Model	Refined Kano Model

Quality Attribute	High Important Attributes	Low Important Attribute

Attractive quality	High attractive quality	Low attractive quality

One-dimensional quality	High value-added quality	Low value-added quality

Must-be quality	Critical quality	Necessary quality

Indifferent quality	Potential quality	Care-free quality


Molecule	Actions/effects	Reference

Sulfur dioxide	Possible long-term cardiac abnormality	Pishgoo et al. (15)

Cardiac and mitochondrial dysfunction (rats)	Qin et al. (1)

Increase heart susceptibility to oxidative stress	Zaky et al. (16)

Inhibits the proapoptotic effect of isopropylarterenol on myocardial tissue through a bcl-2/cytc/caspase-9/caspase-3 pathway	Jin et al. (11)

Aggravates myocardial I/R injury	Zhang et al. (17)

Sulfur dioxide	Ameliorated systemic hypertension and pulmonary hypertension prevented the development of atherosclerosis and protected against myocardial ischemia-reperfusion (I/R) injury and isoproterenol-induced myocardial injury	Huang et al. (18)

Sulfites

Sulfur mustard	Modification of the ratio prooxidant/antioxidant	Shohrati et al. (19)

Reduction of serum GSH, increase of serum malondialdehyde (MDA)

Sulfites	Deleterious effects through the mitochondrial Fe3+ cyt c-mediated ROS	Velayutham et al. (20)

Reduced the length and volume of the ventricular capillaries (rats)	Noorafshan et al. (21)

With sulfite oxidase contributes in NO signaling	Wang et al. (22)

They can affect voltage-gated sodium (Na+) channels (VGSC) in a concentration-dependent manner in isolated rat ventricular myocytes. Protective action of catechins	Wei and Meng (23)


	ST use			RR/OR

Sourcea	Typeb	Exposurec	Smoking	Sex	Id.	Casesd	Estimate (95%CI)	Adjustment factorse

Case-control studies

Wynder et al. 1957 [40]

- larynx cancer	Chew	Ever	Any	M	1	NA	no associationf	none

Vincent and Marchetta 1963 [45]

- larynx cancer	Snuff	Use	Any	M	2	5	1.81 (0.33–9.97)	none

Williams and Horm 1977 [55]

- larynx cancer	ST	Ever	Any	M	3	16	2.01 (1.15–3.51)g	age, race, smok

Wynder and Stellman 1977 [56]

- larynx cancer	Chew	Ever	Any	M	4	46	1.35 (0.96–1.89)g	none

	Snuff				5	15	1.46 (0.82–2.57)g	none

	ST				6	61	1.40 (1.04–1.89)h	none

Engzell et al. 1978 [57]

- nasal cancer	Snuff	Use	Any	M	7	NA	no association	none

Brinton et al. 1984 [64]

- nasal cancer	Chew	Use	Any	M+F	8	15	0.74 (0.40–1.50)	sex

	Snuff				9	23	1.47 (0.80–2.80)

	ST				10	38	1.08 (0.68–1.70)h	none

Stockwell and Lyman 1986 [70]

- nasal cancer	ST	Ever	Any	M+F	11	1	2.93 (0.40–21.66)g	none

- larynx cancer	ST	Ever	Any	M+F	12	6	2.02 (0.84–4.86)g	none

Young et al. 1986 [71]

- larynx cancer	ST	Ever	Any	M	13	NA	no association	none

Lewin et al. 1998 [102]

- larynx cancer	Snuff	Current	Any	M	14	15	1.00 (0.50–1.90)	age, alc, res, smok

		Former			15	9	0.80 (0.40–1.70)

		Ever			16	24	0.90 (0.50–1.50)


GroupNo.	Description	Body site whereS. aureus detectedin Parsonnet 2005studya	Ab present inParsonnet 2005studyb	No. of subjectsenrolledc	No. of subjectscompleting allvisits

1	Carriers of SA TSST-1(+)	Vagina	Yes or No	14	11

2	Carriers of SA TSST-1(+)	Nose or anus	Yes	78	64

3	Carriers of SA TSST-1(-)	Any site	Yes	69	49

4	Non-carriers	None	Yes	75	58

5	Negative Ab control(Carriers or Non-carriers)	Any site	No	75	61


Gay/Lesbian

 	Model 1 (adjusted for socio-demographic characteristics)a	Model 2 (controlling for depressive symptoms)b	% reduction in association controlling for PHQ-9	Sobel test for significance of mediator

Outcome	OR*	(95% CI)	OR*	(95% CI)	 	Z Value	P-Value

Current Smoker	1.843	(1.17, 2.92)	1.812	(1.14, 2.88)	1.68	1.846	0.064

BMI (Overweight/Obese)	1.128	(0.78, 1.64)

Lifetime History of Drug Use (Excluding Marijuana)	1.786	(1.10, 2.91)	1.766	(1.09, 2.87)	1.12	1.4863	0.137

Lifetime History of Marijuana Use	1.753	(1.09, 2.82)	1.746	(1.09, 2.81)	0.40	1.50534	0.132

Risky Drinking (5 or more drinks) in Past 12 months	1.01	(0.61, 1.69)

Lifetime Period of Risky Drinking	1.271	(0.76, 2.12)

Bisexual

 	Model 1 (adjusted for socio-demographic characteristics)a	Model 2 (controlling for depressive symptoms)b	% reduction in association controlling for PHQ-9	Sobel test for significance of mediator

Outcome	OR*	(95% CI)	OR*	(95% CI)	 	Z Value	P-Value

Current Smoker	2.124	(1.65, 2.73)	2.044	(1.59, 2.63)	3.77	3.04054	0.0023

BMI (Overweight/Obese)	0.897	(0.61, 1.31)	 	-	-	-	-

Lifetime History of Drug Use (Excluding Marijuana)	3.381	(2.24, 5.10)	3.301	(2.20, 4.96)	2.37	1.93298	0.0532

Lifetime History of Marijuana Use	2.928	(2.05, 4.19)	2.901	(2.02, 4.16)	0.92	3.44351	<0.001

Risky Drinking (5 or more drinks) in Past 12 months	1.499	(1.05, 2.15)	Cannot Estimate

Lifetime Period of Risky Drinking	2.901	(1.67, 5.04)	Cannot Estimate


Diagnostic Stage	Diagnostic Modality	Sensitivity (%)

Central	Peripheral

Initial Diagnosis	Sputum cytology	71	49

Bronchoscopy	88	78

 Washings	47	43

 Brushings	56	54

 Biopsy	74	57

Radiologically guided transthoracic biopsy	-	90

Radial probe EBUS	-	73

Electromagnetic navigation	-	68

Cryobiopsy	95	74

Linear EBUS TBNA	82	-

Mediastinal Staging	Bronchoscopic TBNA	78

Linear EBUS TBNA	89

EUS	89

EUS + EBUS	91

Video assisted surgical mediastinoscopy	89


MMP	ANOVA	Post Test Results

pMMP-9	p = 0.0817	No significant differences.

aMMP-9	p = 0.0944	No significant differences.

pMMP-2	p = 0.0010	pH 5.6 (24 h) < Positive Control (24 h) (p < 0.05)

		pH 9 (24 h) < Positive Control (24 h) (p < 0.01)

		Negative Control (72 h) < Positive Control (24 h) (p < 0.001)

		Positive Control (72 h) < Positive Control (24 h) (p < 0.05)

		pH 4 (72 h) < Positive Control (24 h) (p < 0.05)

		pH 5.6 (72 h) < Positive Control (24 h) (p < 0.05)

		Negative Control (72 h) < pH 4 (24 h) (p < 0.05)

aMMP-2	p = 0.0019	pH 9 (24 h) < Positive Control (24 h) (p < 0.01)

		pH 9 (24 h) < pH 4 (24 h) (p < 0.05)

		Negative Control (72 h) < Positive Control (24 h) (p < 0.01)

		Negative Control (72 h) < pH 4 (24 h) (p < 0.05)


	Health consumer

Health professional	Integration	Assimilation	Separation	Individualism (Marginalization)

Integration	Consensual	Problematic	Conflictual	Problematic

Assimilation	Problematic	Consensual	Conflictual	Problematic

Separation	Conflictual	Conflictual	Conflictual	Conflictual

Individualism	Conflictual	Conflictual	Conflictual	Conflictual


Variable	Value

 Age (years)	63 (58–73)

 Sex ratio (male/female)	16/9

 Body mass index (kg/m2)	26 (22–27)

 Euroscore 2 (%)	5 (3–8)

 Left ventricular ejection fraction (%)	60 (60–66)

 Preoperative serum creatinine (μmol/l)	76 (59–90)

 Glomerular filtration rate (ml/min/1.73 m2)	82 (75–91)

Comorbidities (n, %)

 Hypertension	15 (60)

 Chronic obstructive pulmonary disease	2 (8)

 Dyslipidemia	11 (45)

 Smokers	6 (24)

Type of surgery (n, %)

 Coronary surgery	8 (32)

 Valve surgery	12 (48)

 Combined surgery	2 (8)

 Other cardiac surgery	3 (12)

 Thoracic surgery	4 (16)

Chronic medications (n, %)

 Beta blockers	10 (40)

 Renin angiotensin system inhibitors	12 (48)

 Statins	11 (44)

 Antiplatelet agents	9 (36)

 Calcium channel blockers	5 (20)

 Nitrates	2 (8)

Vasoactive support

 Norepinephrine at baseline (μg/kg/min)	0.03 ± 0.10

During POAF

 Kaliemia (mmol/l)	4.1 ± 0.4

 Hemoglobin (g/dl)	10.8 ± 1.6

 SpO2 (%)	96.0 ± 1.8


Substance name	Mechanism of action	Clinical trial, design and results	Reference

TAK-242 (Resatorvid)	Binds covalently to Cys747 of TLR4-TIR domain and blocks TLR4/TIRAP and TLR4/TRAM interactions	Randomized, double-blind, placebo-controlled phase 2 trial (274 patients). Failed to suppress cytokine levels in patients with sepsis and shock or respiratory failure.	[124]

Eritoran (E5564)	Lipid A mimic, binds to MD-2	Phase 2, double-blind, placebo-controlled, ascending-dose study (152 patients). Eritoran was well tolerated but did not attenuated systemic inflammation significantly.	[127]

Randomized, double-blind, placebo-controlled, multinational phase 3 trial (1961 patient). Treatment did not improve 28-day survival.	[131]

Prospective, randomized, double-blind, placebo-controlled, multicenter, ascending-dose phase II trial (293 patients). Eritoran was well tolerated but the mortality was not decreased significantly.	[132]


	All patients	Patients with OS >50 months	Patients with OS <50 months	Pvalue

ORR (%)*	44.9	82.6	17.9	<0.00001

CBR (%)*	63.3	100	35.7	<0.00001

TTF*	10	26	5	0

TTP*	18	34	5	0

OS*	38	68	17	<0.00001

OS from diagnosis of MBC	52	113	20	<0.00001

Number Of chemotherapy regimens*	1 (0-3)	1 (0-3)	1 (0-3)	0.66

Number of chemotherapy regimens for BC	3 (1-7)	4 (1-7)	4 (1-6)	0.36

Number of chemotherapy regimens for MBC	3 (1-7)	3 (1-7)	3 (1-5)	0.2


 	PD (n = 14)	CON (n = 17)	P value

 	Means ± SD	Means ± SD

Age (years)	62.79 ± 4.59	61.35 ± 4.27	0.376

Gender*	11 M/3 F	13 M/4 F	0.889

Disease duration (years) 	2.46 ± 1.43	—	—

UPDRS score

 Part I—mood/cognition 	2.93 ± 1.14	—	—

 Part II—activities of daily living 	9.93 ± 2.27	—	—

 Part III—motor examination 	21.79 ± 5.66	—	—

 Part IV—complications of therapy 	0	—	—

MMSE score	23.93 ± 2.13	—	—

VAS	4.77 ± 1.30	5.69 ± 1.25	0.064

WST	37.01 ± 1.44	35.74 ± 1.39	0.022

HPT	47.74 ± 2.09	45.33 ± 3.44	0.042


	SERPINB9	CD83	CD9

	Pool	Indiv	Pool	Indiv	Pool	Indiv

Control	1	1	1	1	1	1

MS	0.5	2.47	1.1	0.58	1.23	3.5


QoL Domains	Mesor	Amplitude	Circadian Quotient	Rhythm Quotient	24-hr Correlation	Night-day Sleep Balance

EORTC Symptom Items

Fatigue			-0.4	-0.41		-0.52

Pain				-0.39

Loss of Appetite						-0.47

EORTC Functional Domains

Social				.34

Role						0.56

Cognitive						0.45

EORTC Global Health item					0.53

Ferrans-Powers QLI Domains

Health/Function	0.44	0.51			0.45	0.39

Social/Economic		0.38	0.39			0.40

Psychological Spiritual		.45		0.4		0.45

Family		0.45


Case	Signs/symptoms	Treatment	R

1	Anorexia, weight loss, fasting hypoglycemia, and mental aberrations	IVH, Di	[12]

2	Weakness, anorexia, orthostatic dizziness, failure to lactate, and weight loss	BB, C	[13]

3	Myalgia, anorexia, nausea, vomiting, weight loss, and failure to lactate	IVH, C 	[14]

4	Lethargy, anorexia, vomiting, and weight loss	IVH, C, AT, RAI	[15]

5	Fatigue, weakness, nausea, vomiting, myalgia, arthralgia, and weight loss	C	[16]

6	Lethargy, myalgia, arthralgia, myopathy, nausea, vomiting, anorexia, weight loss, and failure to lactate	C, AT	[17]

7	Confusion, tachycardia, and dehydration	C, RAI	[17]

8	Disturbed mental state, severe nausea, vomiting, increased thirst, polyuria, and weight loss	AT, C, DDAVP	[4]

9	Anorexia, diarrhea, night sweats, myalgia, and weight loss	IVH, BP, AT, C	[18]

10	Headache, anorexia, weakness, fever, tachycardia, mental changes, and failure to lactate	C, IVH, KI, AT, BB 	[19]

11	Nausea, vomiting, fever, and lethargy	C	[7]

12	Anorexia, nausea, vomiting, and severe dehydration	C, IVH	[20]

13	Vomiting and diarrhea	IVH, BB, C	[21]

PC	Vomiting, nausea, constipation, and weight loss	IVH, C, Di, BP, AT, BB


	Community-based organization Naloxone distribution	Traditional prescription	Pharmacy-based Naloxone models

CPA	Standing medication order	Protocol order	Pharmacist prescribing

Who issues prescription?	Prescriber via standing order	Prescriber	Non-pharmacist prescriber	Non-pharmacist prescriber	Licensing board	Pharmacist

Medical professionals required	Varies by state: prescriber, state/local health department	Prescriber + pharmacist	Prescriber + pharmacist	Prescriber + pharmacist	Pharmacist	Pharmacist

Potential recipients	Individuals served by the community-based organization	Patients of the prescriber	Varies by state	Anyone meeting criteria specified by prescriber	Anyone meeting criteria specified by licensing board	Anyone for whom medication is indicated

Target overdose risk population served	People who use drugs (prescription opioids, heroin) who access the community-based organization*	People who use drugs who are in treatment/visit a prescriber*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*	People who use drugs (prescription opioids, heroin) who visit a pharmacy*

Patients prescribed opioids who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*	Patients filling a prescription for opioids at a pharmacy who are at risk of overdose*

Geographic reach	Limited to where community-based organizations are located and operate	Limited to where the prescriber practices	Any participating pharmacy within the state	Any participating pharmacy within the state	Any participating pharmacy within the state	Limited to where the pharmacist practices


Term	Count	P-value	Genes

Regulation of transcription, DNA-dependent	105	4.82E–06	REST, RORA, ZNF254, HOXC6, TDGF3, GATA6, TDGF1, OLIG2, MLL3, PITX2, NODAL, EMX2, ZNF814, EOMES, SUZ12, HES5, SOX7, LIN28A, NR2C2, ARX, FOXH1, LHX9, DNMT3A, SALL4, FOXA2, NR6A1, PAX3, GLI2, POU5F1, HEY2, ZNF720, SOX10, NANOG, DMRT3, OTX2, RUNX1T1, SPEN, HAND1, ISL1, POU5F1B, ATRX, RBAK, THRAP3, PBX2

Embryonic morphogenesis	26	3.44E–04	RBP4, FOXA2, PAX3, GLI2, TDGF3, SPRY2, HAND1, PRKRA, TDGF1, CEP290, NODAL, EOMES, PCDH8, CFC1, DKK1, SALL4, GNAQ, HOXB6, LRP6, PTCH1, MAB21L2, PBX2

Lung development	11	0.004697	SPRY2, RBP4, FOXA2, PDGFA, GATA6, DHCR7, NODAL, VEGFA, GLI2, FOXP1, KDR

Regulation of neurogenesis	13	0.026608	PHOX2B, NBN, BMP2, FOXA2, REST, ISL1, GLI2, RUFY3, HES5, CCND2, NUMB, NEFM, ASPM

Forebrain development	16	7.60E–04	OTX2, EMX2, GLI2, ISL1, AHSG, ARX, SALL3, ATRX, FEZF2, DKK1, GNAQ, NUMB, PAFAH1B1, LRP8, RELN, ASPM

Neuron differentiation	32	8.12E–04	FGFR1, FOXA2, ONECUT2, GRIN3A, PAX3, RORA, GLI2, PTEN, CXCL12, KLHL1, ARX, KAL1, NUMB, CEP290, OLIG1, PAFAH1B1, OLIG2, RET, BHLHE22, OTX2, EMX2, LIFR, ISL1, CDKN1C, SALL3, FEZF2, EPHA4, ADM, GNAQ, HES5, VEGFA, RELN

Cerebral cortex development	6	0.008017	ARX, EMX2, LRP8, PAFAH1B1, RELN, AHSG

Telencephalon development	7	0.038287	ARX, SALL3, EMX2, LRP8, PAFAH1B1, RELN, AHSG


Type of complication 	Prevalence N (%)

Retinopathy	6 (0.9)

LVH	12 (2)

IHD	51 (8.3)

HF	75 (12.2)

CKD	20 (3.3)

Hypertensive urgency	39 (6.4)

Sexual dysfunction	4 (0.67)

Stroke	34 (5.5)

AF	6 (0.9)

Total TOD	247 (100.0)


Malalignment parameter	Difference compared to pre-opMedian (IQR)	Significancea

Cutting guide (n = 4)	Visualisation (n = 4)

Coronal shift in mm, ulnar (−), radial (+)	3.1 (1.9 to 10.0)	−2.6 (−3.0 to 3.5)	0.200

Sagittal shift in mm, volar (−), dorsal (+)	10.2 (−7.3 to 18.1)	−6.7 (−26.4 to −2.6)	0.200

Radial length in mm	2.2 (−2.0 to 15.7)	4.3 (0.3 to 5.4)	0.686

Palmar tilt in deg, dorsal (−), volar (−)	−6.8 (−24.5 to 4.4)	8.5 (5.2 to 14.9)	0.114

Radial inclination in deg, ulnar (−), radial (+)	−3.2 (−9.3 to 5.7)	0.3 (−11.4 to 5.3)	1.000

Axial rotation in deg, pronation (−), supination (+)	23.0 (11.5 to 30.6)	1.8 (−13.1 to 30.0)	0.343


Analyte	Concn (ng/ml)

Low	High

Amodiaquine	4.0	4,192

Desethylamodiaquine	4.0	4,192

Lumefantrine	25	20,000

Chloroquine	4.0	4,192

Desethylchloroquine	4.0	4,192

Dihydroartemisinin	1.6	2,875

Piperaquine	1.2	575

Mefloquine	70	4,000

Carboxymefloquine	70	4,000

Primaquine	10	400

Carboxyprimaquine	50	4,000


	Panitumumab + mFOLFOX6 (n = 88)	Bevacizumab + mFOLFOX6 (n = 82)*

Median DoR, months (95% CI)	11.4 (10.0, 16.3)	9.0 (7.6, 9.5)

 HR† (95% CI)	0.59 (0.39, 0.88)

 p value‡	0.011

Median TTR, months (95% CI)	2.3 (1.9, 3.7)	3.8 (2.1, 5.7)

 HR† (95% CI)	1.19 (0.81, 1.74)

 p value‡	0.37

Median DpR, % (Q1, Q3)	65.0 (45.7, 89.5)	46.3 (29.5, 63.3)

 p value¶	0.0018

Any resection, n (%)	12 (14)	9 (11)

 Liver only§	9 (75)	6 (67)

Complete resection	9 (10)	7 (9)

 Liver only^	7 (78)	6 (86)

Time to resection, months – median (range)	5.1 (3–19)	4.4 (3–12)

Progression-free at 6 months, n (%)

 Patients with resection	8/12 (67)	4/9 (44)

 Patients without resection	45/76 (59)	48/73 (66)

Alive at 2 years, n (%)

 Patients with resection	8/12 (67)	8/9 (89)

 Patients without resection	18/76 (24)	12/73 (16)


Gene	Encoded protein	Fold change	Cell cycle

AURKA	Aurora kinase A	−2.712	STOP

AURKB	Aurora kinase B	−4.146	STOP

CCNA2	Cyclin A2	−4.652	STOP

CCNB1	Cyclin B1	−5.752 −5.820 −5.857	STOP

CCNB2	Cyclin B2	−3.392	STOP

CCND1	Cyclin D1	−2.476	STOP

CCND3	Cyclin D3	−1.539	STOP

CCNE1	Cyclin E1	−1.777	STOP

CCNE2	Cyclin E2	−2.847	STOP

CCNF	Cyclin F	−3.211	STOP

CDC6	Cell division cycle 6	−1.936	STOP

CDC20	Cell division cycle 20	−3.113	STOP

CDC25B	Cell division cycle 25B	−1.636	STOP

CDC25C	Cell division cycle 25C	−2.414	STOP

CDC45	Cell division cycle 45	−1.769	STOP

CDCA2	Cell division cycle associated 2	−3.461	STOP

CDCA3	Cell division cycle associated 3	−3.003	STOP

CDCA5	Cell division cycle associated 5	−3.053	STOP

CDCA7L	Cell division cycle associated 7-like	−4.123	STOP

CDCA8	Cell division cycle associated 8	−3.467	STOP

CDK1	Cyclin-dependent kinase 1	−3.227	STOP

CDK15	Cyclin-dependent kinase 15	1.618	GO

CDK19	Cyclin-dependent kinase 19	1.619	GO

CDK5R1	Cyclin-dependent kinase 5, regulatory subunit 1 (p35)	1.597	—

CENPA	Centromere protein A	−1.895	STOP

CENPE	Centromere protein E, 312 kDa	−4.140	STOP

CENPF	Centromere protein F, 350/400 kDa	−3.927	STOP

CENPI	Centromere protein I	−2.899	STOP

CENPK	Centromere protein K	−2.813	STOP

CENPL	Centromere protein L	−1.864	STOP

CENPM	Centromere protein M	−3.407	STOP

CENPN	Centromere protein N	−2.465	STOP

CENPU	Centromere protein U	−1.624	STOP

SKA1	Spindle and kinetochore associated complex subunit 1	−1.532	STOP

SKA2	Spindle and kinetochore associated complex subunit 2	−1.582	STOP

SKA3	Spindle and kinetochore associated complex subunit 3	−3.490	STOP

SKP2	S-phase kinase-associated protein 2, E3 ubiquitin protein ligase	−1.845	STOP

SPC25	SPC25, NDC80 kinetochore complex component	−4.148	STOP


	Criteria	Assessment

1	A diagnosis of PD	Queen's Square Brain Bank Criteria

2	PD developed prior to the onset of dementia	Patient/caregiver history or ancillary records

3	PD associated with a decreased global cognitive efficiency	MMSE < 26

4	Cognitive deficiency severe enough to impair daily life	Caregiver interview or pill questionnaire

5	Impairment of more than one cognitive domain	Impairment of at least two of the following domains

		Attention

		Executive function

		Visuo-constructive ability

		Memory


Case/sex/age (years)	Initial treatment	Associated pseudocyst	Rebleeding	Secondary treatment	Length of follow-up (months)	Outcome

1/M/59	A	No	No	No	57	S

2/M/33	TG, L	No	No	No	38	S

3/M/46	E	Yes*	Yes	E‡, L, ED	4	D

4/F/71	E	No	Yes	E	18	S

5/M/36	Nearly TP, Sp	No	No	No	50	S

6/M/33	DP+	Yes*	Yes	E‡, L, ED	87	S

7/M/28	DP, Sp	Yes+	No	GC+	15	S

8/M/38	A, ED	Yes+	No	RD	51	S

9/M/35	DP, Sp	Yes	No	No	10	S


Materials	Size (L = Length; W = Width; H = Height)

Grinding media	Steel ball (∅15 mm)	Square (L: 12 × W: 12 × H: 12 mm)	Cylinder (∅12 × H: 16 mm)

Iron ore particle	2–2.8 mm

Lifter	L: 40 × W: 20 × H: 10 mm	L: 40 × W: 20 × H: 15 mm	L: 40 × W: 20 × H: 20 mm


Number of examined samples	n (%)

Pure buffalo samples	Adulterated samples

50	5 (10)	45 (90)


Menopausal symptoms	Number (%)	Severe	Very severe

Somatic

Sleeping problems	574 (78.7)	93	1

Hot flushes, sweating	508 (69.7)	157	75

Joint and muscular discomfort	500 (68.6)	86	0

Heart discomfort	360 (49.4)	0	0

Psychological

Physical and mental exhaustion	536 (73.5)	68	4

Depressive mood	402 (55.2)	109	12

Irritability	339 (46.5)	105	10

Anxiety	334 (45.8)	114	7

Urogenital

Dryness of vagina	449 (61.6)	102	4

Bladder problems	385 (52.8)	38	2

Sexual problems	343 (47.1)	56	6


Mechanism	Source	Description

Soluble CD25	RS cells	Prevent interaction of IL-2 with IL-2Rs

IL-10	RS cells, Tregs, cells of TME	Repress IL-2 and IFN-γ production

TGF-β	RS cells, Tregs, cells of TME	Repress IL-2 and IFN-γ productionDownregulate activating receptors (NKG2D, NKp30) and corresponding ligands (MICA, ULBP2, ULBP4)

IL-15	RS cells	Competition of RS cells and NK cells

CXCL9, CXCL10	RS cells (mainly EBV+)	Attract CD56bright–CD16dim NK cells

HLA-G and HLA-E	RS cells	Bind to inhibitory receptors on NK cells

Soluble MICA	RS cells	Endocytosis and degradation of NKG2D

BAG6/BAT3	RS cells	Endocytosis and degradation of NKp30

Rosetting	Macrophages, Tregs, Th2 T-helper cells	Physical shield of HRS cells from NK cells

c-FLIP	Overexpressed by RS cells	NK FasL-mediated apoptosis resistance

FasL	RS cells	Apoptosis of Fas-expressing NK cells

PD-L1	RS cells	Suppression of NK cell activation

MHC-I	RS cells (EBV+)	Bind to KIRs, inhibit NK cell activation


Variables	Lower-Grade Glioma	Glioblastoma

Numbers	170	133

Median age (range)	39 (10–75)	49 (8–81)

Sex (male)	103	86

Pathology (Astrocytic)	69	-

IDH1 mutational status	-	-

IDH1 mutation	100	18

IDH1 wild-type	34	78

1p/19q status	-	-

1p/19q co-deletion	34	2

No 1p/19q co-deletion	108	106


Characteristic	N (%) or Mean ± SD

Sex

 Female	183 (70.4 %)

 Male	77 (29.6 %)

Age (years)	38.8 (13.7)

Referral source

 Primary Care	231 (88.8 %)

 Respirologist	7 (2.7 %)

 Allergist	2 (0.8 %)

 Other	10 (3.8 %)

 Unknown	10 (3.8 %)

Diagnosis of atopy

 Allergic rhinitis	120 (46.2 %)

 Asthma	90 (34.6 %)

 Atopic dermatitis	61 (23.5 %)

 Venom allergy	5 (1.9 %)

 Drug allergy	42 (16.2 %)

 Urticaria	60 (23.1 %)

 Eczema	61 (23.5 %)

 Pollen food syndrome	35 (13.5 %)


Absorbed dose to the thyroid (Gy)	Number of differentially expressed transcripts	Number of up- and down-regulated transcripts

0.05	1,225	↑ 338

 	 	↓ 887

0.5	1,636	↑ 480

 	 	↓ 1,156

1.4	544	↑ 284

 	 	↓ 260

11	575	↑ 412

 	 	↓ 163

32	425	↑ 293

 	 	↓ 132


	N (%)

Lesion location

Right upper lobe	40/68 (58.8)

Right middle lobe	21/68 (30.9)

Right lower lobe	22/68 (32.4)

Left upper lobe	33/68 (48.5)

Left lower lobe	21/68 (30.9)

Lesion distribution

Bilateral	30/68 (44.1)

Multilobar (≥3 lobes with abnormalities)	21/68 (30.9)

Lesion characteristics

Multiple nodules	42/68 (61.8)

Bronchiectasis	24/68 (35.3)

Cavity	13/68 (19.1)

Unilateral	9/68 (13.2)

Bilateral	4/68 (5.9)

Radiographic classification

Upper lobe cavitary pattern	12/68 (17.6)

Nodular bronchiectatic pattern	17/68 (25.0)

Unclassifiable	39/68 (57.4)


 	Normal	Borderline	Case

Anxiety

Baseline (n=37)	28	6	3

3 months (n=37)	30	5	2

6 months (n=28)	20	6	1

Depression

Baseline (n=37)	31	4	2

3 months (n=37)	31	4	2

6 months (n=28)	23	4	1


Variants	P-value

Age at diagnosis	0.249

Gender	0.543

WBC at diagnosis	0.533

Bone marrow blasts	0.733

Peripheral blasts	0.406

FLT3-ITD positive	0.153

NPM1 mutation	0.031

CEBPA mutation	0.050


Coefficients	Estimate	Std. Error	t Value

(Intercept)	−1.222e + 02	1.251e + 02	−0.977

SWB	−4.421e − 03	4.916e − 02	−0.090

SDI	9.152e − 02	5.400e − 02	1.695

Dallas Theological Seminary	−5.706e − 01	1.473e + 00	−0.387

Denver Seminary	1.066e − 00	1.629e + 00	0.655

Gordon-Conwell Seminary	2.005e − 01	1.541e + 00	0.130

Oral Roberts University	2.190e − 02	2.209e + 00	0.010

Male	−3.381e + 00	1.364e + 00	−2.478

Birth Year	7.702e − 02	6.276e − 02	1.227

Non-Hispanic White or Euro-American	2.627e + 00	1.295e + 00	2.028

Latino or Hispanic American	8.577e + 00	2.872e + 00	2.987

Other/Multi-Racial	−5.138e + 00	3.248e + 00	−1.582


	Recall	Precision	F-score

Any	79.46	78.45	78.95

Unrelated	60.26	70.59	65.02

Altered expression	77.96	79.90	78.91

Genetic variation	77.76	82.45	80.04

Regulatory modification	69.17	73.28	71.16

Overall	76.61	79.46	78.00


Key words	Other variations of key words

NCDs metabolic risk factors plus proximal determinants plus distal determinants plus geographic location	NCDs metabolic risk factors	High blood pressure, hypertension, high blood glucose, hyperglycemia, diabetes, high BMI, obesity, overweight, waist circumference, waist-hip ratio

Proximal determinants	Determinants, risk, diet, salt intake, tobacco, smoking, alcohol, physical inactivity, lifestyle

Distal determinants	Social determinants, education, income, gender, race, caste, ethnicity, socio-economic status, wealth index, income

South Asia	Nepal, India, Bangladesh, Pakistan, Sri Lanka, Bhutan, Maldives, Afghanistan


	FeNO	CalvNO	nNO

Asthma	Normal/increased	Normal/increased	Normal/increased

COPD	Normal/increased	Increased	NS

CF	Normal/decreased	Contradictory results	Decreased

PCD	Normal/decreased	Contradictory results	Decreased

Allergic rhinitis	Normal/increased	Normal	NS

BPD	Normal/decreased	Decreased	NS

HPS	Decreased	Increased	NS

PAH	Decreased	Increased	NS

SSc	Normal/decreased	Increased	NS

Rhinovirus infection	Increased	NS	NS

Allograft rejection	Increased	NS	NS


KEGGID	Pvalue	Count	Size	Term

4530	0.011	3	11	Tight junction

533	0.046	1	1	Keratan sulfate biosynthesis

604	0.046	1	1	Glycosphingolipid biosynthesis - ganglio series

1031	0.047	2	8	Glycan structures - biosynthesis 2

4620	0.047	2	8	Toll-like receptor signaling pathway

51	0.059	2	9	Fructose and mannose metabolism

4210	0.059	2	9	Apoptosis

3010	0.064	3	21	Ribosome

52	0.089	1	2	Galactose metabolism

512	0.089	1	2	O-Glycan biosynthesis

720	0.089	1	2	Reductive carboxylate cycle (CO2 fixation)

5213	0.089	1	2	Endometrial cancer

5218	0.089	1	2	Melanoma

5223	0.089	1	2	Non-small cell lung cancer


Gene	Abbreviation	Teleost accession number	Transcript in the greater amberjack	In silico group	DE* male vs female gonads	Sex determining in

DM domain gene on the Y chromosome/ doublesex and mab-3-related transcription factor 1a	dmY/dmrt1a	Oryzias latipes NM_0 011 04680/ XM_004086451 unplaced scaffold	maker-jcf7180000931253-snap-gene-0.40-mRNA-1	SD7	Up in male gonads	Oryzias latipes [23, 65]

Gonadal soma-derived factor	gsdf	Oryzias latipes NM_0 011 77742 chr.12	Augustus-masked-jcf7180000916295-processed-gene-0.7-mRNA-1	SD17	Up in male gonads	Oryzias luzonensis [66]

Y chromosome–specific antimuellerian hormone	amhY	Oryzias latipes NM_0 011 04728 chr. 4	maker-jcf7180000931145-snap-gene-0.73-mRNA-2	SD4	Up in male gonads	Odontesthes hatcheri [67] HM153803.1

Antimuellerian hormone receptor 2	amhr2	Lates calcarifer KR492510 Oryzias latipes DQ499644.1 chr. 5 or 7	maker-jcf7180000889430-snap-gene-0.77-mRNA-5	SD1	No expression	Takifugu genus [68]

Sexually dimorphic o the Y chromosome	sdY	Salmonidae family	n/a	n/a	n/a	Salmonidae family [69]

SRY-box containing protein 3Y	sox3Y	Oryzias latipes AJ245396 chr.10	augustus-masked-jcf7180000920392-processed-gene-0.31-mRNA-1	SD18	Up in female gonads	Oryzias dancena [65]


Number of women (percentage)	357	(92%)

Median years of age (IQR)	52	(8)

Median years of age diagnosed with a pain disorder (IQR)a	30	(18)

Median PPI (IQR)	4	(3)

Median number of comorbid pain conditions (IQR)	3	(2)

Median number of current pain medications (IQR)	3	(3)

Median number of past pain medications (IQR)	6	(7)


	Nurses	Controls

N	32	30

Age (in years)	40.3 (11.3)	40.0 (12.3)

Sex (male/female)	7/25	3/27

Education	lower secondary school (Hauptschule)	7	4

Intermediate secondary school (Realschule)	18	22

Higher education entrance qualification (Abitur) (finished or enrolled)	5	4

University degree	2	0


Dependent variable	Fivefolded cross-validated R2 (%)	Effect size, f2

MUSICIANS ONLY

Judgment line orientation	15	0.18

Letter-number sequencing	14	0.16

Tower rule violations	0	0.00

Letter fluency	0	0.00

CVLT-II SDFR	0	0.00

Grooved pegboard – dominant hand	29	0.21

Grooved pegboard – non-dominant hand	28	0.20


Welding Positions	No. of Butt Welds	Laser Beam Power, W	Traveling Speed, m/min	Heat Input, kJ/m

Vertical up	U01	2200	0.5	275

U02	2500	1.2	125

Vertical down	D01	2200	0.5	275

D02	2500	1.2	125


Category	Term	Count	P-value	Benjamini

KEGG_PATHWAY	Cytokine-cytokine receptor interaction	24	9.00E-07	1.30E-04

GOTERM_BP_FAT	Immune response	18	1.90E-03	2.50E-01

GOTERM_CC_FAT	Extracellular region part	15	1.60E-02	6.30E-01

GOTERM_MF_FAT	Cytokine activity	14	1.80E-03	1.90E-01

GOTERM_CC_FAT	Extracellular space	14	2.10E-02	4.90E-01

KEGG_PATHWAY	Natural killer cell mediated cytotoxicity	13	8.10E-04	5.50E-02

KEGG_PATHWAY	Chemokine signaling pathway	13	3.20E-02	2.90E-01

GOTERM_BP_FAT	Defense response	12	1.40E-02	4.60E-01

KEGG_PATHWAY	Jak-STAT signaling pathway	12	1.80E-02	2.00E-01

KEGG_PATHWAY	T cell receptor signaling pathway	10	1.50E-02	2.10E-01

KEGG_PATHWAY	Hematopoietic cell lineage	9	1.10E-02	1.80E-01

KEGG_PATHWAY	Toll-like receptor signaling pathway	9	2.30E-02	2.40E-01

KEGG_PATHWAY	NOD-like receptor signaling pathway	8	5.50E-03	1.40E-01

KEGG_PATHWAY	Allograft rejection	8	7.40E-03	1.60E-01

GOTERM_BP_FAT	Response to wounding	8	1.30E-02	5.10E-01

KEGG_PATHWAY	Fc epsilon RI signaling pathway	8	1.70E-02	2.10E-01

KEGG_PATHWAY	Asthma	7	2.00E-03	6.80E-02

GOTERM_BP_FAT	Inflammatory response	7	7.90E-03	3.90E-01

KEGG_PATHWAY	Cytosolic DNA-sensing pathway	7	8.20E-03	1.50E-01

KEGG_PATHWAY	Autoimmune thyroid disease	7	5.70E-02	4.20E-01

GOTERM_BP_FAT	Chemotaxis	6	1.40E-02	4.20E-01

GOTERM_MF_FAT	Cytokine binding	6	3.40E-02	8.60E-01

GOTERM_BP_FAT	Locomotors behavior	6	3.40E-02	7.10E-01

KEGG_PATHWAY	Graft-versus-host disease	6	4.30E-02	3.60E-01

INTERPRO	Immunoglobulin	6	4.50E-02	9.00E-01

KEGG_PATHWAY	Type I diabetes mellitus	6	6.90E-02	4.70E-01

GOTERM_BP_FAT	Behavior	6	7.90E-02	9.20E-01

GOTERM_BP_FAT	Cell migration	5	1.80E-03	4.30E-01

GOTERM_BP_FAT	Cell motility	5	3.30E-03	2.90E-01

INTERPRO	Small chemokine, C-C group, conserved site	5	5.50E-02	8.80E-01

GOTERM_BP_FAT	Leukocyte migration	4	6.40E-03	4.00E-01

INTERPRO	Chemokine receptor	4	6.40E-02	8.70E-01

GOTERM_MF_FAT	C-C chemokine receptor activity	4	7.20E-02	9.40E-01

GOTERM_MF_FAT	C-C chemokine binding	4	7.20E-02	9.40E-01

GOTERM_MF_FAT	Chemokine receptor activity	4	9.50E-02	9.40E-01


Characteristics	OCP-patch (N = 30)	LTS-2 patch (N = 30)

Definition of reaction	At 24 h	At 30 h	At 24 h	At 30 h

 None	3 (10.0)	2 (6.7)	5 (16.7)	0

Oedema under the patch (any score)	NA	NA	25 (83.3)	30 (100)

 100 % of area oedematous (score 3)	NA	NA	17 (56.7)	27 (90.0)

> 50 % of area oedematous (score 2)	NA	NA	4 (13.3)	3 (10.0)

< 50 % of area oedematous (score 1)	NA	NA	4 (13.3)	0

 0 % of area oedematous (score 0)	NA	NA	5 (15.7)	0

 All reactions	27 (90.0)	28 (93.3)	25 (83.3)	30 (100)

Very easily visible reaction	18 (60.0)	24 (80.0)	22 (73.	19 (63.3)

Easily visible reaction	2 (6.7)	3 (10.0)	0	1 (3.3)

Attentive visual inspection required	7 (23.3)	1 (3.3)	3 (10.0)	10 (33.3)

Character of papules

 None	3 (10.0)	2 (6.7)	5 (16.7)	0

 Vague	4 (13.3)	1 (3.3)	3 (10.0)	0

 Pinheads	16 (53.3)	16 (53.3)	0	0

 Pinpoints	7 (23.3)	11 (36.7)	19 (63.3)	29 (96.7)

 Urticariform	0	0	3 (10.0)	1 (3.3)

Extension beyond patch area	2 (6.7)	8 (26.7)	0	0


Studies	Reported outcomes	Follow up period	Bias grade

Brar2008	Death, MI	9.7 months	-

I-LOVE IT 2	NACCE, death, MI, stroke, TVR, TLR, ST, all bleeding, major bleeding	12 and 18 months	B

ISAR-SAFE	Primary endpoints, death, MI, ST, stroke, TIMI major and minor bleeding, BARC bleeding	9 months	B

Tarantini2016	Death, MI, composite endpoints, stent thrombosis, BARC type 3 or 5 bleeding, stroke, revascularization	1 year	-

ARCTIC	Primary endpoints, Death, MI, ST, stroke, revascularization	17 months	B

OPTIMIZE	NACCE, death, MI, stroke, ST, major bleeding, TLR, TVR, any bleeding	1 year	B

RESET	Primary endpoints, death, MI, TVR, ST, major and minor bleeding, stroke	1 year	B

EXCELLENT	Death, MI, stroke, TVR, TLR, ST, any bleeding, TIMI major bleeding	1 year	B

PEGASUS	Death, MI, stroke, TIMI major and minor bleeding	3 years	B

DAPT	ST, MACCEs, death, stroke, MI, BARC type 2,3 or 5	12 to 30 months	B

Sardella2011	Death, MI, stroke, TIMI minor bleeding, revascularization	2 years	-

PRODIGY	Death, MI, stroke, ST, TLR, TVR, TIMI major and minor bleeding, BARC bleeding	2 years	B

Thukkani2015	Death, MI, Stroke	4 years	-

ENDEAVOR	Death, MI, ST (definite and probable), stroke, major bleeding	2 years	B

ITALIC	Primary endpoints, minor bleeding, minimal bleeding, death, MI, stroke, TVR, ST, major bleeding	1 year	B


	User-initiated (n = 17)	Not user-initiated (n = 3)

User investigator	14	–

External user involved since formulation	2	1

External user involved only in interpretation	1	2


Markers	Staining intensity

LNCaP	Spheres	Neuroendocrine cells

Pancytokeratin	+/−	-	+++

Neuro-specific enolase	+/−	−	+++

Serotonin	−	−	+


	certified CAM	noncertified CAM	COM

	mean	median	mean	median	mean	median

Number of patients per year	652	537	955	899	987	906

Number of consultations per year	2797	2440	3811	3726	3918	3783

- Disease related	2746	2421	3694	3621	3822	3731

- Accident related	40	14	100	76	82	46

- Other (maternity, unclassified)	12	2	17	3	13	2

- Number of home visits	79	30	268	181	304	211

Number of consultations per patient and year	4.6	4.2	4.1	3.9	4.2	4.0


	EEG normal patients = 53(%)	EEG abnormal patients = 17(%)

palpitations, pounding heart, or accelerated heart rate	44 (83.0)	13 (76.5)

sweating	11 (20.8)	5 (29.4)

trembling or shaking	16 (30.2)	5 (29.4)

sensations of shortness of breath or smothering	40 (75.5)	13 (76.5)

feeling of choking	13 (24.5)	4 (23.5)

chest pain or discomfort	22 (41.5)	7 (41.2)

nausea or abdominal distress	20 (37.7)	14 (82.4)

feeling dizzy, unsteady, lightheaded, or faint	38 (71.7)	15 (88.2)

derealization or depersonalization	4 (7.5)	8 (47.1)

fear of losing control or going crazy	23 (43.4)	11 (64.7)

fear of dying	16 (30.2)	5 (29.4)

paresthesias	23 (43.4)	11 (64.7)

chills or hot flushes	11 (20.8)	7 (41.2)

age	34.6 ± 9.3	33.9 ± 9.8

sex	M:17F:36	M: 3F:14


Costs per patient in different situation in CHF	CMR strategy	“hypothetical” CXA strategy

All tests performed as outpatient procedures in Switzerland	1,984	2,580

CXA performed as an inpatient procedure in Switzerland	2,408	4,638


Sensor	Targeted Gases	Smell Description

TGS 880	volatile vapors from food	food (while cooking)

TGS 825	hydrogen sulfide	rotten egg, sulfurous smells

TGS 826	ammonia	old rotten urine and fish (sharp, penetrating, and irritating smell)

TGS 822	alcohol, xylene, toluene, other VOC	aromatic solvents, wood fermentation, alcoholic beverages

TGS 2610	general hydrocarbons	smell of ripening fruits

TGS 2602	ammonia, hydrogen sulfide,ethanol, toluene	a wide range of smell: from rotten fish to wood fermentattion


 	PinX1

Positive	Negative	P

Sex

Male	34	74

Female	7	43	0.020

Age

<60 years	19	52

≥60 years	22	65	0.834

Smoking status

Yes	34	76

No	7	41	0.034

Histology

Squamous	36	65

Adenocarcinoma	5	52	0.000

Lesion

Peripheral	28	83

Central	13	34	0.750

Tumour location

Left	17	48

Right	24	69	0.961

Resection type

Lobectomy	35	95

Pneumonectomy	3	19

Other	3	3	0.163

Metastasis

Yes	15	67

No	26	50	0.023

T stage

T1	6	41

T2 + T3	35	76	0.013

N stage

N0	46	24

N1 + N2	17	71	0.033

TNM stage

I	13	31

II	17	32

III	11	54	0.082


Toxicity	Grade

	0	1	2	3	4	≥Grade 3 (%)

Leukopenia	26	16	17	3	0	5

Neutropenia	32	14	11	5	0	8

Anemia	28	31	3	0	0	0

Thrombocytopenia	33	27	2	0	0	0

Mucositis	1	15	45	1	0	2

Dermatitis	1	58	2	1	0	2

Hoarseness	45	12	4	1	0	2


Test substance	Tomato extract in squalane	Tomato extract in hydrogenated polydecene	Dunaliella extract in hydrogenated polydecene

Reactions noted	None	None	None

# reactive subjects (%)	0 (0%)	0 (0%)	0 (0%)

MDIS	0	0	0

Conclusion	Very good skin compatibility/nonirritant	Very good skin compatibility/nonirritant	Very good skin compatibility/nonirritant


Antibiotic	Proportion susceptible (%)

 	MSSA (n = 80)	MRSA (n = 6)

Cefoxitin	100	0

Benzylpenicillin	26	0

Co-trimoxazole	60	0

Tetracycline	85	0

Gentamicin	99	0

Ciprofloxacin	100	0

Erythromicin/Clindamycin	99	17

Rifampicin	99	83

Chloramphenicol	100	100

Vancomycin	100	100

Mupirocin	100	100


Polymer Type	LOD	Response Time/Recovery Time	Transducing Mechanism	Ref.

PPy nanoparticles	5 ppm	Less than 1 s/2 s	Chemiresistive	[58]

Multidimensional PPy nanotubes	0.01 ppm	Less than 1 s/55–60 s	Chemiresistive	[113]

Single PPy nanowire	40 ppm	15–10 min (for 40–300 ppm)/15 min for 40 ppm	Chemiresistive	[36]

PPy nanowires	1.5 ppm	60 s for 73 ppm/prolonged with increasing of con. (1.5–73 ppm)	Chemiresistive	[18]

Single crystal PPy nanotube	0.00005 ppm	~16 s/~16 s for 1 ppm	Chemiresistive	[114]

PPy nanoribbons	0.5 ppm	~8 min/3 min	Chemiresistive	[62]

PPy nanotubes PPy/Ag–AgCl composite Nanotubes	–	>1000 s for 100 ppm/−150 s for 100 ppm/500 s	Chemiresistive	[115]

PPy/ZnO nanocomposite PPy/SnO2 nanocomposite	10 ppm	~100 s for 24 ppm/100 s ~50 s for 24 ppm/250 s for first 3 cycles	Chemiresistive	[13]

PPy/graphene nanocomposite decorated with TiO2 nanoparticles	1 ppm	~36 s/~16 s for 50 ppm	Chemiresistive	[116]

Au/PPy nanopeapods	0.007 ppmv	~15 min for 5 ppmv/did not reach Ro value	Chemiresistive	[117]


Variable	HIV-1-seronegative psoriasis	HIV-1-related psoriasis	References

Frequency	1-3%	Similar to HIV-seronegative population	[54,55]

Severity	Mild-moderate	Moderate-severe	[62]

Clinical features	Erythematous plaques usually circumscribed to elbows-knees (psoriasis vulgaris)	More extensive lesionsIncreased presence of acral lesions and inverse psoriasis	[4,55]

Histhopatological features	Hyperproliferation and hyperkeratosis, lymphocytic infiltrate and absence of granular layer	Same	[55]

Presence of psoriatic arthritis	5-20%	23%-50%	[54,55]

Mean age of presentation	>30 years	=30 years	[63]

Family history	Frequent	Variable	[64]

Presence of HLA-Cw*0602	25%	79%	[64]

Presence of Reiter's Syndrome	Rare	Frequent	[54]

Development of erythroderma	+/+++	++/+++	[65]

Response to conventional treatment (topical steroids, Vitamin D analogues, phototherapy)	Variable	Variable-poor	[63,66]

Response to zidovudine/HAART	+/+++	++/+++	[67,68]


Group	Hoffman cluster	Species, subspecies, or complex	Type strain	Accession no.	No. of strains

A	VI	E. xiangfangensis	LMG 27195a	NZ_CP017183.1	3

B	VIII	E. hormaechei subsp. steigerwaltii	DSM 16691a	NZ_CP017179.1	83

C	VI	E. hormaechei subsp. oharae	DSM 16687a	NZ_CP017180.1	104

D	III	E. hormaechei	DSM 14563a	NZ_CP017186.1	30

E	VII	E. hormaechei subsp. hormaechei	ATCC 49162	GCA_000213995.1	5

F		E. mori	LMG 25706	AEXB00000000	1

G	XI	E. cloacae subsp. cloacae	ATCC 13047	NC_014121.1	11

H	XII	E. cloacae subsp. dissolvens			4

I	V	E. ludwigii	EN-119	CP017279.1	11

J	I	E. asburiae	ATCC 35953	NZ_CP011863.1	30

K		E. cloacae complex			6

L		E. cloacae complex			7

M	IV	E. cloacae complex	DSM 16690a	NZ_CP017184.1	31

N		E. cloacae complex			3

O		E. cloacae complex			1

P		E. cloacae complex			4

Q	II	E. kobei	DSM 13645a	NZ_CP017181.1	31

R	IX	E. cloacae complex			14


Variables	Patients number	%

Age (mean ± SD) days	6.7 ± 2.3

Body weight (mean ± SD) kg	3.4 ± 0.3

Gender

 Male	13	68.4

 Female	6	31.6

Diagnosis

 TGA with VSD	2	10.5

 Taussig–Bing	17	89.5

Arch anomaly

 Coarctation of aorta	13	68.4

 Interruption	6	31.6

 Type A	2	10.5

 Type B	4	21.1

Coronary artery pattern

 1L,Cx; 2R	8	42.1

 1L; 2Cx,R	2 (1RP)	10.5

 1R; 2L,Cx	3 (2RP)	15.8

 1R,L; 2Cx	1 (RP)	5.3

 2L,Cx,R	1 (IM)	5.3

 2L,Cx; 2R	3 (1RP, 1IM)	15.8

 2R; 2L,Cx	1 (RP)	5.3

Relation of gas

 Anteroposterior	4	21.1

 Side by side	15	78.9

PGE1	19	100

Mechanical ventilation	3	15.8


		Odds ratio	95 % confidence intervals

			Lower	Upper

Tobacco	Follow-up vs. Baseline	1.020	0.223	4.661

Nutrition	Follow-up vs. Baseline	1.555	0.814	2.972

Physical activity	Follow-up vs. Baseline	0.946	0.476	1.879

Screening	Follow-up vs. Baseline	2.788*	1.166	6.663

Clinical trials	Follow-up vs. Baseline	3.118*	1.372	7.083


Diet composition	20% animal protein	10% animal pro+tein	20% plant protein	10% plant protein

Total energy value (kcal/g)	3.7	3.7	3.7	3.7

Carbohydrate (%Kcal)	62.93	73.23	63.15	73.06

Fat (%kcal)	16.97	16.97	16.87	16.74

Protein (%Kcal)	20.11	10.04	19.98	10.20

Leucine (g/kg)	18.7	9.4	21.2	10.6

Isoleucine (g/kg)	10.1	5.0	7.9	4.0

Lysine (g/kg)	15.7	7.9	3.9	1.9

Methionine (g/kg)	4.9	2.4	4.1	2.1

Cysteine (g/kg)	2.0	1.0	3.0	1.5

Arginine (g/kg)	6.7	3.3	7.8	3.9

Phenylalanine (g/kg)	8.8	4.4	10.4	5.2

Tyrosine (g/kg)	9.2	4.6	5.0	2.5

Histidine (g/kg)	4.9	2.4	4.2	2.1

Threonine (g/kg)	8.4	4.2	5.5	2.7

Tryptophan (g/kg)	2.5	1.2	1.6	0.8

Valine (g/kg)	11.8	5.9	8.7	4.3

Wheat gluten (g/kg)	―	―	110	55

Corn gluten (60%) (g/kg)	―	―	136	68

Isolated soy protein (g/kg)	―	―	22	11

Casein (g/kg)	170	85	―	―

Lactalbumin (g/kg)	44	22	―	―

Corn starch (g/kg)	380.1	486.3	325.4	459

Maltodextrin (g/kg)Sucrose (g/kg)	100150	100150	100150	100150

Corn oil (g/kg)	32	32	32	32

Olive oil (g/kg)	32	32	32	32

Cellulose (g/kg)	50	50	50	50

Mineral Mix, w/o Ca & P	13.14	13.14	13.14	13.14

Calcium phosphate (g/kg)	8	10.8	12	12.6

Calcium carbonate (g/kg)	10.3	8.3	7.0	6.8

Vitamin Mix, Tekland (g/kg)	10	10	10	10


 	 	<underline>Mean (SD)</underline>

Age	(Year)	43.91 (15.4)

Pain intensity*	(0–10)	4.11 (1.9)

Physical disability**	(0–24)	8.78 (5.3)

Depression***	(0–42)	8.75 (9.9)

Anxiety≠	(0–42)	6.55 (8.4)

Stress±	(0–42)	13.08 (9.8)

Fatigue†	(1–63)	32.49 (12.3)

Pittsburgh questionnaire#	(0 – 21)	7.92 (3.8)

Insomnia index$	(0 – 28)	11.25 (6.4)

Epworth scale¥	(0 – 24)	7.26 (5.2)

Body mass index	(Kg/m2)	25.73 (4.9)

 	 	<underline>N (%)</underline>

Pain duration	Acute	32 (41%)

 	Chronic	47 (59%)

Roland item£	(Yes)	46 (58%)

Seeking care	(Yes)	58 (73%)

Taking pain medication	(Yes)	35 (44%)

Gender	(Female)	40 (51%)

Level of education	(University degree)	35 (44%)

Smoking status	(Not)	74 (94%)

Work status	Full-time	48 (61%)

 	Part-time	14 (18%)

 	Not working	4 (5%)

 	Retired	13 (16%)

Marital status	Married or defacto	39 (49%)

 	Separated	8 (10%)

 	Single	32 (41%)


	Full sample (n = 14,798)	Restricted analytic sample (n = 11,733)

	percent	std error	percent	std error

Age

18–24	17	0.6	18	0.6

26–44	53	0.9	55	1.0

45–64	30	0.8	28	0.9

Gender

Men	49	0.4	49	0.5

Women	51	0.4	51	0.5

Race/ethnicity

White	74	1	75	1

Black	12	0.6	11	0.6

Mexican-American	6	0.5	6	0.5

Other	8	0.9	8	1

Marital status

married/living as	64	0.9	64	0.9

not married/not living as	36	0.9	36	0.9

Education

< high school	23	1	22	1

high school	35	0.8	34	0.8

> high school	42	1	44	1

Occupation

white collar and professional	24	0.9	25	0.9

white collar, semi-routine	23	0.7	23	0.7

blue collar, high skill	12	0.5	12	0.5

blue collar, semi-routine	39	0.8	38	0.9

never worked	3	0.3	3	0.3

Income (equivalized for family size)

< 50% median	22	1	21	1

50–100% median	31	1	30	1

> median	47	2	49	2

% below poverty	11	0.7	11	0.8

% poverty to 184% poverty	16	0.8	15	0.8

185% poverty to median income*	25	1	25	1

> median*	47	2	49	2

Work and health

not currently in labor force	25	0.7	21	0.7

employment affected by health	10	0.4	0	-

death with <1 year follow-up	0.3	0.07	0	-


Variable	Number of cases	%

Gender

 Male	116	54

 Female	98	46

Age, y

 < 70	120	56

 ≥ 70	94	44

T-category

 T2	33	15

 T3	181	85

Cancer specific survival, y

 < 5	105	49

 ≥ 5	109	51

 Censored	156	73


SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS	QUALITY OF LIFE

	Physical	Psychological	Level of independence	Social relationships	Environment	Spirituality/Religion/Personal beliefs

Age*	-0.01	0.04	-0.17†	-0.03	0.10	0.03

Duration of diabetes in years (since first diagnosis)**	-0.02	0.09	-0.17†	-0.02	0.09	0.07

Fasting Glucose mmol/L**	-0.08	-0.15†	-0.00	-0.09	-0.18†	-0.00

HbA1c %*	-0.05	-0.05	-0.00	-0.00	-0.11	0.00


HPA	Position	Common allele	Rare allele	Residue variety in β-integrins

1	33	Leu	Pro (Val)	A, D, E, G, K, L, M, N, P, Q, S, T, V, Y

4	143	Arg	Gln	A, E, G, K, N, Q, R, S, T, V

6	489	Arg	Gln	A, D, E, G, H, K, N, P, Q, R, S, T, V

7	407	Pro	Ala	D, E, H, I, K, L, P, Q, R, S, T, V

8	636	Arg	Cys	D, E, G, H, K, L, N, P, Q, R, S, T, Y

10	62	Arg	Gln	D, E, F, H, I, K, L, N, Q, R, S, T, V

11	633	Arg	His	A, D, E, G, H, K, L, N, Q, R, S, T, V

14	611	Lys	del	D, F, H, K, L, N, Q, R, S, Y

16	140	Thr	Ile	A, D, E, G, K, L, N, Q, R, S, T, V


Demographic or Clinical Characteristic	No. of Patients (N= 48)	%

Age, years

 Median		56.6

 Range		29-77

ECOG performance status

 0	19		39.6

 1	23		48

 2	6		12.5

Primary tumor intact	11		23

Skin ulceration	19		40

Lymph node stations clinically involved

 Groin only (stage III)	11		23

 Deep inguinal or pelvic (stage IV)	28		58.3

Distant metastasis	21		43.7

History of smoking	40		83

 Current	6		12.5

 Former	34		70.8

Prior treatment

 Chemotherapy	19		39.6

 Radiation therapy	5		10.4

Presentation of disease

 Primary	17		35.4

 Recurrent	31		64.6


Effects and limitations of management contract	Public sector perspective	private sector perspective

Effects	By introducing competitive forces, contracting puts pressure on both public and private providers in terms of both service and price.	Contracting expands market opportunities to include public sector clients or customers.

Expanding the range of activities subject to contracting encourages the private sector to expand the services it provides in areas desired by government.	Contracting allows a private provider to capture a market to be protected from competitors at least for the term of the contract.

Contracting both requires and promotes better planning and policy development by improving the flow of information about volumes of goods, services, costs, quality, responsiveness, population served, health needs and other issues.	Contracting can provide a reliable and timely source of revenue, encouraging investments necessary to support quality and innovation and ensuring longer term viability.

Contracting provides government with a mechanism for purchasing needed health services at an agreed on and therefore predictable price.	The contract term may provide adequate time to justify investments in the capital and personnel needed to support contractual obligations.

Contracting promotes transparency, constrains conflicts of interest and reduces opportunity for graft and corruption.

Limitations	Qualified private providers may not be available.	The costs of entering the market to compete successfully for government contracts may be too high.

Qualified bidders may not be interested in contracting with government.	The market may be too unstable or the contract period too short to support needed capital investments.

Competition may be weak or non existent.	Transaction costs, the costs of securing and managing the contract may be too high.

Government may discourage bidders by shifting too much risk to providers.	There may be no legal resource if government fails to fulfill its contractual obligations.

Successful contractors could compete with the public sector for health personnel.

Governmental capacity to negotiate contracts may be weak.

Government's managerial and bureaucratic overhead may increase.

Government may agree to disadvantages contract terms.

Long term contracts may restrict government flexibility.

Costs may be higher than anticipated.


	No. herds	End of one year study period	Herd size Cow years/year	Calculated bulk tank somatic cell count	Milk production Kg ECM/day	Mastitis treatments % cows treated/cow year	% of cows with infection risk > 50%

Conventional	20	03–2000	83	283	25.7a	74a	42

Organic before 1995	18	03–2000	88	296	22.1c	48b	38

Converting herds before conversion	19	04–1999 or 04–2000	87	317	24.6a,b	61a,b	42

Converting herds first year after conversion	19	04–2000 or 04–2001	101	337	23.3c	52a,b	44

Converting herds second year after conversion	19	04–2001 or 04–2002	107	327	23.8*	48a,b	45

Conventional herds in full research project	109	03–2000	85	309	24.4b	55*	43


History of blood donation	Blood donation total attitude	P value*

score (4–20)

Median	Mean rank

Yes	16.5	196.0	<0.001

No	16	157.2


Percentage of 13-to 17-Year-OldGirls Completing HPV Vaccine Series, U.S., 2012

Range	State	Percent	Range	State	Percent

≥50%	Rhode Island	57.7		Kentucky	34.9

	Delaware	50.4		Missouri	34.5

40–49%	Vermont	46.2		New Hampshire	34.5

	Pennsylvania	44.6		Minnesota	33.1

	Hawaii	43.4		Michigan	32.2

	Connecticut	43.6		Ohio	31.9

	Washington	43.5		South Dakota	31.8

	Massachusetts	43		New Jersey	31.6

	Maine	41.8		Alaska	31.4

	Montana	41.6		Alabama	31.1

	North Dakota	40.9		Maryland	30.9

	Louisiana	40.5		New Mexico	30.3

30–39%	New York	39.7		Texas	30.3

	Oregon	38.6		Wyoming	30.3

	District Columbia	38.5	≤29%	Georgia	29

	Oklahoma	38.4		Tennessee	28.6

	Colorado	38		Virginia	27.9

	Wisconsin	37.5		Idaho	27.8

	Nebraska	37.3		South Carolina	26.6

	Nevada	37.2		Florida	25.3

	Arizona	36.9		Kansas	25.1

	West Virginia	36.1		Utah	24.1

	North Carolina	35.5		Illinois	21.1

	California	35.8		Arkansas	18.3

	Iowa	35.6		Mississippi	12.1

	Indiana	35.2


Diagnosis	Tumour biopsy	Perilesional skin	Total

 	No. of positive/total (%)	No. of positive/total (%)	No. of positive/total (%)

BCC	31/50 (62)	24/50 (48)	55/100 (55)

SCC	8/9 (89)	6/9 (67)	14/18 (78)

Total	39/59 (66)	30/59 (51)	69/118 (58)


PAH	TEF	Surgeon	 	AT

PAHGas	PAHParticle	PAHGas	PAHParticle

Naphthalene	0.001	1055	1.6	584	1.1

Acenaphthylene	0.001	5.8	ND	3.5	ND

Acenaphthene	0.001	19.9	ND	14.6	ND

Fluorene	0.001	55.4	0.8	42.2	0.5

Phenanthrene	0.001	84.3	3.2	68.3	2.2

Anthracene	0.01	22.2	5.6	16.7	4.0

Fluoranthene	0.001	18.9	3.8	14.2	2.7

Pyrene	0.001	17.8	5.4	13.3	4.1

Benzo[a]anthracene	0.1	ND	2.7	ND	1.3

Chrysene	0.01	ND	3.0	ND	1.4

Benzo[b]fluoranthene	0.1	ND	2.6	ND	1.3

Benzo[k]fluoranthene	0.1	ND	1.5	ND	0.7

BaP	1	ND	1.7	ND	1.1

Indeno[cd]pyrene	0.1	ND	1.8	ND	1.0

Dibenzo[ah]anthracene	5	ND	1.8	ND	1.1

Benzo[ghi]peryrene	0.01	ND	2.1	ND	1.5

BaPeq	1.5	11.4	0.9	7.2

Calculated lifetime cancer risk (×10-6) based on 24-hr exposurea	131	992	78	626

Risk of unit-hour exposure (×10-6)	46.8	29.3

Average operation time (hour/day)	2.5	9.2

Estimated lifetime cancer risk (×10-6)	117	270


Enrichment Categories	p-Value	FDR	Related Genes

GO processes

Negative regulation of eicosanoid secretion	7.5 × 10−9	3.0 × 10−6	Hrh2, F2rl2

Glucocorticoid biosynthetic process	1.6 × 10−8	3.8 × 10−6	Cacna1h, Hsd3b1

Negative regulation of fatty acid transport	4.1 × 10−8	7.6 × 10−6	Hrh2, F2rl2

System process	4.5 × 10−7	4.5 × 10−5	Actc1, Lmod3, Cacng1, Des, Dcdc2, Tnni2, Hrh2, Myog, Cacna1h, Lmod2, F2rl2, Mb, Rasl10b, Olr1714

Response to hormone	1.1 × 10−6	8.5 × 10−5	Actc1, Lyn, Slco1b2 Dmbt1, Hsd3b1, Myog, Cacna1h, Hrh2, Myb, F2rl2

Cellular component morphogenesis	1.2 × 10−6	8.9 × 10−5	Actc1, Cacna1h, Hrh2, F2rl2, Lyn, Dcdc2, Lmod2, Lmod3, Ntn1

Regulation of neurotransmitter secretion	2.5 × 10−6	1.5 × 10−4	Cacna1h, Cacng1, Hrh2

Calcium ion transmembrane transport	3.6 × 10−6	2.0 × 10−4	Cacna1h, Cacng1, Hrh2

Positive regulation of gamma-aminobutyric acid secretion	3.9 × 10−6	2.1 × 10−4	Hrh2, F2rl2

Calcium ion transport	5.1 × 10−6	2.5 × 10−4	Cacna1h, Cacng1, F2rl2, Hrh2

Diseases (in biomarkers)

Autistic disorder	1.5 × 10−5	8.9 × 10−4	Cacna1h, Hrh2, F2rl2

Child development disorders, pervasive	1.6 × 10−5	9.0 × 10−4	Cacna1h, Hrh2, F2rl2

Communication disorders	6.1 × 10−5	2.3 × 10−3	Dcdc2, Hrh2

Language disorders	6.1 × 10−5	2.3 × 10−3	Dcdc2, Hrh2

Mental disorders diagnosed in childhood	8.8 × 10−5	3.0 × 10−3	Cacna1h, Dcdc2, Hrh2

Tourette syndrome	1.3 × 10−4	4.1 × 10−3	Hrh2, F2rl2

Tic disorders	1.3 × 10−4	4.2 × 10−3	Hrh2, F2rl2

Epilepsy, absence	1.7 × 10−4	4.8 × 10−3	Cacna1h, Cacng1

Neurotoxicity syndromes	2.1 × 10−4	4.8 × 10−3	Hrh2, F2rl2

Pathological conditions, signs and symptoms	5.6 × 10−4	9.1 × 10−3	Des, Dcdc2, Ntn1, Cacng1, Cacna1h, Hsd3b1, Tnni2, F2rl2, Mb, Dmbt1, Actc1, Nags, Napb


Organism	<1 mo	1-11 mos	1-55 yrs	6-12 yrs	> 12 yrs	Age Unk	Total	% of total

Streptococcus pneumoniae	2	31	27	17	87	42	187	37.18

Neisseria species	2	5	14	18	56	12	107	21.27

Haemophilus species	0	18	24	2	9	6	59	11.73

Staphylococcus	0	10	6	2	11	7	36	7.16

Others Gram negative	0	11	2	0	7	2	22	4.39

Escherichia coli	1	2	1	0	15	3	22	4.37

Streptococcus species	 	 	 	 	 	 	19	3.77

Other Gram positives	0	4	3	1	5	0	13	2.6

Enterococcus species	0	3	0	2	1	3	9	1.79

Acinetobacter species	0	4	0	2	2	0	8	1.59

ESBL’s Klebsiella pneumoniae	4	2	0	0	0	1	7	1.39

Klebsiella	0	1	1	0	4	1	7	1.39

Pseudomonas species	0	2	2	1	2	0	7	1.39

Total	9	93	80	45	199	77	503	100.02


Ecological		Levels	Change in change

Model	Dependent variable	PCNSDP	PCDE	HCR	PCNSDP	PCDE	HCR

1	Stunting prevalence	−1.92**	–	–	−0.87	–	–

(0.45)	–	–	(0.69)	–	–

2	Stunting prevalence	–	−5.41**	–	–	1.39	–

–	(0.89)	–	–	(1.47)	–

3	Stunting prevalence	–	–	0.55**	–	–	0.20

–	–	(0.08)	–	–	(0.14)


ID	Annotation	290 vs. 5532 fold change	290 vs. 5532 – p-value corrected FDR	Normalized expression means 290	Normalized expression means 5532

APOBEC3A	Probable DNA dC- > dU-editing enzyme APOBEC-3A	1.80E+308	0.022	0.000	8.304

BLZF1	Golgin-45	1.80E+308	0.000	0.000	19.258

BTBD11	Ankyrin repeat and BTB/POZ domain-containing protein BTBD11	1.80E+308	0.000	0.000	17.621

CRLF2	Uncharacterized protein	1.80E+308	0.000	0.000	75.314

CSF1	Uncharacterized protein	1.80E+308	0.022	0.000	8.313

CXCL10	C-X-C motif chemokine 10	1.80E+308	0.000	0.000	134.604

CXCL11	C-X-C motif chemokine 11	1.80E+308	0.000	0.000	27.796

DDX58	DEAD (Asp-Glu-Ala-Asp) box polypeptide 58	1.80E+308	0.013	0.000	9.386

DDX60	Probable ATP-dependent RNA helicase DDX60	1.80E+308	0.000	0.000	17.559

DDX60L	Probable ATP-dependent RNA helicase DDX60-like	1.80E+308	0.048	0.000	6.609

EIF2AK2	Interferon-induced, double-stranded RNA-activated protein kinase	1.80E+308	0.006	0.000	11.043

EPSTI1		1.80E+308	0.013	0.000	9.460

GPNMB	Transmembrane glycoprotein NMB	1.80E+308	0.001	0.000	16.139

GYPA	Glycophorin-A	1.80E+308	0.000	0.000	33.703

HERC6	Probable E3 ubiquitin-protein ligase HERC6	1.80E+308	0.030	0.000	7.652

IDO1	Uncharacterized protein	1.80E+308	0.000	0.000	38.529

IFI35	Interferon-induced 35 kDa protein	1.80E+308	0.000	0.000	23.808

IFI44L	Interferon-induced protein 44-like	1.80E+308	0.009	0.000	10.133

IFIT1	Uncharacterized protein	1.80E+308	0.000	0.000	39.978

IFIT3	Interferon-induced protein with tetratricopeptide repeats 3	1.80E+308	0.006	0.000	11.063

IFIT5	Interferon-induced protein with tetratricopeptide repeats 5	1.80E+308	0.001	0.000	14.751

IFITM1	Interferon-induced transmembrane protein 1	1.80E+308	0.000	0.000	41.506

NT5C3	Cytosolic 5′-nucleotidase 3	1.80E+308	0.026	0.000	7.949

PARP9	Uncharacterized protein	1.80E+308	0.032	0.000	7.461

PLSCR1	Phospholipid scramblase 1	1.80E+308	0.002	0.000	13.466

RSAD2	Radical S-adenosyl methionine domain-containing protein 2	1.80E+308	0.003	0.000	12.711

SEPP1	Uncharacterized protein	1.80E+308	0.000	0.000	20.263

SLC39A8	Zinc transporter ZIP8	1.80E+308	0.033	0.000	7.413

SPARC	Uncharacterized protein	1.80E+308	0.013	0.000	9.466

XAF1	XIAP-associated factor 1	1.80E+308	0.003	0.000	12.311

SP110	Uncharacterized protein	6.58E+00	0.000	242.916	1598.704

SAMD9	Uncharacterized protein	–3.18E+00	0.010	27.623	8.683

ADAM19	Uncharacterized protein	–3.18E+00	0.008	29.217	9.184

DSG2	Desmoglein-2	–6.36E+00	0.000	33.496	5.264

SLCO5A1	Uncharacterized protein	–1.27E+01	0.000	47.197	3.709

PGAP1	GPI inositol-deacylase	–1.91E+01	0.000	51.117	2.678

SIGLEC1	Sialoadhesin	–5.09E+01	0.000	112.694	2.214

BRIP1	Fanconi anemia group J protein	–1.80E+308	0.000	23.188	0.000

SGPP2	Sphingosine-1-phosphate phosphatase 2	–1.80E+308	0.000	1262.355	0.000


Follow-up periods	P value for lab data

	Hemoglobin	TLC	Platelets	Bilirubin	ALT	AST

Before therapy versus after 1 month	0.00	0.78	0.19	0.00	0.00	0.00

After 1 month versus after 3 months	0.285	0.06	0.25	0.00	0.00	0.00

After 3 months versus after 6 months	0.15	0.11	0.35	0.002	0.001	0.00

After 6 months versus after 1 year	0.97	0.16	0.303	0.00	0.013	0.00


Species	GenBank Accession	Reference

Bathymodiolus azoricus	AF334663	[70]

B. thermophilus	AF334664	[70]

Crassostrea virginica 1	AB206328	[58]

Crassostrea virginica 2	AB252064	[57]

Crassostrea virginica 3	AB427186	This paper

Calyptogena sp. SB2001_1	AF334666	[70]

Calyptogena sp. SB2001_2	AF334667	[70]

Crassostrea gigas 1	AB179775	[96]

Crassostrea gigas 2	AB288344	[97]

Crassostrea gigas 3	AB307634	[65]

Crassostrea gigas 4	CU994883	Favrel, direct submission

Chlamys islandica	AJ250028	[52]

Eisenia andrei	DQ339138	Joskova et al. direct submission

Hirudo medicinalis	U24122	[98]

Mytilus edulis 1	AF334662	[70]

Mytilus edulis 2	DQ268868	Caponera and Rawson direct submission

Mytilus galloprovincialis 1	AF334665	[70]

Mytilus galloprovincialis 2	AB298451	Itoh et al. direct submission

Ostrea edulis	AB179776	[96]

Tapes japonica	AB091383	[64]


Day of follow up	0	1	2	3	7	14	21	28

Patients assessed at visit	176	173	172	172	172	171	171	171

Loss to follow up	0	3	1	0	0	1	0	0


Term	MAPP Network Research Definition

Urologic chronic pelvic pain syndrome (UCPPS)	General term to describe idiopathic chronic pelvic pain of urologic origin in men or women. In MAPP Network studies, this includes men and women with IC/BPS, or men with CP/CPPS (see below).

Interstitial cystitis/bladder pain syndrome (IC/BPS)	Chronic unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms, in the absence of infection or other identifiable causes.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)	Chronic idiopathic pelvic pain or discomfort in males, commonly in the perineum, suprapubic region, penis, or testicles, which is often exacerbated by ejaculation or urination.

Non-Urologic Associated Syndromes (NUAS)	General term used to describe symptom-based non-urologic syndromes which co-occur with UCPPS at a rate greater than observed in the general population. Within the MAPP Network, initial efforts have focused on studying specific NUAS (fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome), though other examples exist (e.g. vulvodynia, temperomandibular joint disorder, and migraine headaches, among others).


Dose	Direction	Striatum	Hippocampus	Cortex

10 mg/kg	Up in YAC128, Down with pridopidine	3.58E-04	3.78E-04	2.40E-04

Down in YAC128, Up with pridopidine	3.64E-04	4.99E-02	2.40E-04

30 mg/kg	Up in YAC128, Down with pridopidine	3.15E-04	3.46E-04	2.35E-04

Down in YAC128, Up with pridopidine	3.37E-04	3.53E-03	2.35E-04


Number	Age (years)	Sex	Primary hematological disorder	Organs involved by tuberculosis	Diagnosis of tuberculosis	Treatment/Outcome of tuberculosis

1	55	Male	Chronic myeloid leukemia	Intestine, mesentry and abdominal lymph nodes	Positive lymph node histology and cultures	Given/Successful

2	40	Male	Acute myeloid leukemia	Lungs	Positive sputum cultures	Given/Successful

3	19	Female	Acute myeloid leukemia	Lungs	Positive sputum cultures	Given/Successful

4	20	Female	Hodgkin's lymphoma	Lungs, liver and abdominal lymph nodes	Positive sputum cultures	Given/Successful

5	33	Female	Thrombocytopenic purpura	Cervical lymph nodes	Positive lymph node cultures	Given/Successful

6	70	Male	Hairy cell leukemia	Lungs, liver, spleen, cerebrospinal fluid and bone marrow	Positive cultures(4 sites) and bone marrow histology	Given/Unsuccessful *Multi-drug resistance

7	32	Male	Multiple Myeloma	Lungs	Positive sputum cultures	Given/Successful

8	36	Female	Essential thrombocythemia	Lungs	Positive sputum cultures	Given/Successful

9	24	Male	Acute myeloid leukemia	Lungs, bone marrow and liver.	Positive bronchial lavage	Not given/Death

10	45	Male	Severe aplastic anemia	Lungs	Positive sputum cultures	Not given/Lost follow up

11	70	Male	Myelodysplastic syndrome	Lungs and cervical lymph nodes	Empirical/positive lymph node histology	Given/Successful

12	62	Male	Polycythemia rubra vera	Cervical lymph nodes	Empirical/positive lymph node histology	Given/Successful

13	38	Male	Acute myeloid leukemia	Lungs, bone marrow, psoas muscle and vertebrae.	Empirical/positive muscle and bone marrow histology	Given/Successful

14	52	Female	Chronic myeloid leukemia	Lungs	Empirical/positive serology	Given/Successful

15	59	Male	Myelodysplastic syndrome	Lungs	Empirical/positive serology	Given/Successful

16	75	Male	Myelodysplastic syndrome	Cervical spine	Empirical	Given/Successful

17	60	Female	Myelofibrosis	Lungs	Empirical	Given/Successful

18	65	Male	Chronic myeloid leukemia	Lungs	Empirical	Given/Successful


Clinical parameter	AFAP1‐AS1	Chi‐squared test P value

High no. cases	Low no. cases

Age (years)			0.449

≤64	25	12

>64	25	8

Gender			0.451

Male	37	13

Female	13	7

Smoking state			0.880

Yes	24	10

No	26	10

Drinking state			0.508

Yes	41	15

No	9	5

Tumor size			0.040

≤3 cm	14	12

3–5 cm	29	7

>5 cm	7	1

Tumor stage			<0.01

I	2	11

II	27	4

III	21	5


Imprecision	Event	Original Text	English Translation

	Basel, Jul. 1480	“Anno 1480 circa Magdalenae ingens fuit aquarum inundatio. Rhenus in tantum crevit, quod ad lateres usque inferioris muri Minoris Basileae circa litus ascendit. Etiam homines in ponte stantes facile in Reno manus lavare poterunt.” [Bernoulli, 1915, p. 210]	In 1480, around Magdalena('s day) there was a huge flood of waters. The Rhine rose to the sides of the lower walls of Lesser Basel, near the shore. People standing on the bridge could wash their hands in the Rhine.

small	Meiningen, Jan. 1820	“Nachdem (18. Jan.) mehrere Tage strenge Kälte gewesen war, trat Thauwetter ein und am 20. Jan. war in Folge desselben die Werra aus den Ufern getreten daßdas Wasser die Chaussee am obern Rafen überstieg.” (Chronik)	After that for some days strong coldness occurred, and then melting, and as a consequence on 20 January the Werra left its bed and the water exceeded the promenade on the upper stage.

	Szeged, Jul. 1816	“Alább in a Te(kinte)tes N(eme)s Tanácsnak Kegyes rendeléséhez képpest alázatossan jelentem hogy a Tisza vize, a Maros vízének szörnyü és az idein legnagyobb mostani kiöntése miáll szüntelen árad úgy hogy a múlt Julius 8ik napjátúl fogva 2 Hüvelknyire Fölmagossodott melly szerént a Tiszának az idei legnagyobb aradásátúl fogva esett apadása 20 Hüvelknyit tészen. Szeged 12ik Julii 816. Vedres István”	Letter to the Locumtenential Council: Below, following the order of the esteemed noble council, I report that the water of the Tisza, due to the horrible and in this greatest present inundation of the waters of the Maros, is constantly increasing, and so from the (past) 8 July it increased with 2 inches and thus, the total decrease of the water level of the Tisza compared to the highest levels takes 20 inches. Szeged, 12 July 1816. Istvan Vedres

	Basel, Jul. 1570	“Umb dise zeit ist auch der Rhein so großworden/daßer innerhalb der Statt von dreyen Rhein‐Thoren under der Bruck zusamen geflossen/und die Brucken einem Holz‐floßauff dem Wasser gleich gesehen.” [Groß, 1624, p. 210]	Around this time the Rhine was also so large that it flowed together under the bridge through the three Rhine‐gates in the downtown, and the bridge looked like a wooden raft on the river.

medium	Meiningen, Jun. 1816	“Dreimal trat die Werra aus den Ufern; der ganze Grund stand gegen 14 Tage auf dem Halme aus und die wenige Frucht, die man ärndtete und feucht einfuhr, gab schlechtes Brod.” (Chronik, p. 197)	The Werra left its banks three times; water was on the whole ground covering the stalks and the little grain people harvested, gave bad bread.

	Szeged, 1741	“... preter quod enim quod eadem exundatio agris seminaturas Prata et Pendentes in Vinejs agris fructus in Locis praeterea Marusio et Tibisco Vicinis totaliter perfuderit, et in nihilum redegerit etiam in forejs quod Miser Incola n(on) sui sustentatione conservabat inundavit et Usui humani redidit inutile” (CsCP)	..., and beyond that the same inundation completely flooded the arable lands (with crops), pastures, vineyards and orchards along the Maros and Tisza rivers, and gave nothing to people, and became useless for human use.

	Basel, 1268	“Renus crevit usque adeo, quod omnes pontes destruxit.” (Ann., p. 193)	The Rhine rose so much that it destroyed all bridges.

large	Meiningen, May 1818	“Nach anhaltenden Regenwetter trat die Werra aus den Ufern. Am 18. Mai war die Ueberschwemmung am bedeutendsten.” (Chronik, p.205)	After persistent rainy weather the Werra left its banks. The flooding was the most significant on 18 May.

	Szeged, 1731	3o. “Ioanni Hegedüs, ex quo exundatio aquarum modernam Domum residentionalem destruxisset,...” (SzCP)	The house of Janos Hegedüs has been destroyed by the recent flood,...


		Low prescribers (n = 408)	High prescribers (n = 408)

		Number	Percent	[95% confidence interval]	Number	Percent	[95% confidence interval]

Gender	Female	116	28.4	[24.2–33.1]	118	28.9	[24.6–33.6]

Male	292	71.6	[66.9–75.8]	290	71.1	[66.4–75.4]

Practice location	Rural	110	27.0	[22.8–31.6]	80	19.6	[15.9–23.9]

Urban	298	73.0	[68.4–77.2]	328	80.4	[76.1–84.0]

GP partially particular mode of practice	Yes	40	9.8	[7.2–13.2]	13	3.2	[1.8–5.5]

No	368	90.2	[86.9–92.9]	395	96.8	[94.5–98.2]

Cessation of activity during the year 2010	Yes	7	1.7	[0.8–3.7]	7	1.7	[0.8–3.7]

No	401	98.3	[96.3–99.2]	401	98.3	[96.3–99.2]

		Mean		[Standard deviation]	Mean		[Standard deviation]

Age of GPs		52.6		[9.39]	52.8		[8.10]

Cumulative years of medical practice		19.83		[10.71]	20.5		[9.7146]

Number of consultations and home visits		3,982		[1,994]	3,863		[1,758]

Number of different patients per year		1,106		[538]	1,012		[396]

Number of registered patients		701		[406]	732		[346]

Mean age of patients		46.3		[6.02]	45		[6.1]

Number of patients with low income		60		[79]	45		[48]

Number of patients with chronic disease		145		[91]	144		[80]

Number of days of Sickness certificates prescribed		3,608		[2,537]	3,571		[2,225]

Number of patients prescribed a sickness certificate		100 [64]			94		[50]

Total volume of reimbursement (number of units)		28,247		[17,316]	26,565		[14,477]

Number of prescriptions orders		3,847 [2,122]			3,808		[1,859]

% ≥ 70 new AD		0.86		[0.34]	0.95		[0.20]

Number of DDD		9,163		[6298]	14,848		[8,200]

AD prescription ratio		0.30		[0.09]	0.60		[0.27]


Item		N	Time 1 (Pre)	Time 3 (6 Month)	Mean change*	P value*

			Mean	SD	Mean	SD	Mean	95% CI

1	I am confident that I have the interview skills to use my time well with suicidal clients.	59	51.69	21.60	68.83	16.33	17.14	12.88 – 21.39	0.000

2	After seeing a client once I would be confident that I could recognise potential suicide risk.	59	37.44	21.33	58.05	20.07	20.61	14.96 – 26.26	0.000

3	I feel confident that I could differentiate a mild depression from a suicide risk.	59	49.95	23.14	68.37	16.20	18.42	13.29 – 23.56	0.000

4	I am confident in dealing with the needs of suicidal clients.	59	42.75	21.95	65.98	17.16	23.24	18.53 – 27.95	0.000

	Total	59	181.83	74.59	261.24	61.20	79.41	63.55 – 95.26	0.000


Author, year	Study population (period)	Definition of HDP-related SAMM	Case fatality rate (Number of deaths/cases)	Mortality reductiona

				Natural case fatality

				25%	42%

Mantel et al, 1998[73]	Kalafong and Pretoria hospitals, South Africa (1996-1998)	Hypertension with organ failure	20.8% (10/48)	16.7%	50.4%

Khosla et al 2000[74]	One hospital, Rohtak, India (1998)	Eclampsia	17.7% (11/62)	29.0%	57.8%

Pattinson et al, 2003[75]	Three regions, South Africa (year not stated)	Hypertension with organ failure	20.7% (30/145)	17.2%	50.7%

Kaye et al 2003[76]	Mulago hospital, Uganda (2000)	Eclampsia/pre-eclampsia with organ failure	14.3% (3/21)	42.9%	66.0%

Oladapo et al 2007[77]	Olabisi Onabanjo hospital, southwest Nigeria (2002-2004)	Eclampsia and severe pre-eclampsia with clinical/laboratory indications for termination of pregnancy to save the woman's live	14.9% (21/141)	40.4%	64.5%

Adisasmita et al 2008[78]	Four hospitals in West-Java, Indonesia (2003-2004)	Eclampsia and pre-eclampsia with organ failure	3.9% (22/563)	84.4%	90.7%

Roost et al 2009[79]	Four public hospitals in La Paz and El Alto, Bolivia (2006-2007)	Eclampsia and pre-eclampsia based on clinical and management criteria	0.5% (1/184)	98.0%	98.8%


Characteristic	Number of patients(%)

Sex

Female	318 (29.1)

Male	775 (70.9)

Age (years)

Median

(range)	47 (15-90)

≤ 47	568

> 47	517

Missing	8

Follow-up time (months)

Median	67 (1-120)

(range)

Clinical stage

I-II	315 (29.0)

III-IV	773 (71.0)

Missing	5

Relapse

No	1001 (91.7)

Yes	91 (8.3)

Missing	1

Metastasis

No	984 (90.1)

Yes	108 (9.9)

Missing	1

Therapeutic modality

Radiotherapy	766 (70.6)

Chemotherapy	10 (0.9)

Radiochemotherapy	309 (28.5)

Missing	8

WHO histological classification

NKUC	853 (78.3)

NKDC	206 (18.9)

KSCC	30 (2.8)

Missing	4

OS rate (%)

5-year	69.1


Parameter	Benign (n = 102)	Malignant (n = 11)	P value

Age	58.9 ± 16.4	48.8 ± 18.7	0.059

Female gender	66 (64.7)	5 (45.5)	0.209

Urgent intervention	22 (21.6)	10 (90.9)	<0.01

Coronary artery disease	8 (7.8)	0 (0.0)	0.335

Valvular heart disease	12 (11.8)	0 (0.0)	0.229

Congenital heart disease	0 (0.0)	1 (9.1)	0.742

Thromboembolic disease	3 (2.9)	0 (0.0)	0.564


Hospital	Case (male/female)	Percentage of total

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine	178 (111/67)	5.03%

Guanganmen Hospital affiliated to China Academy of Chinese Medical Science	564 (363/201)	15.95%

Huairou Hospital of Traditional Chinese Medicine	121 (77/44)	3.42%

Beijing Hospital of Traditional Chinese Medicine	220 (142/78)	6.22%

People's Hospital affiliated to Beijing University	107 (72/35)	3.03%

Tongzhou Hospital of Traditional Chinese Medicine	160 (98/62)	4.52%

Tongren Hospital affiliated to Capital University of Medical Sciences	260 (162/98)	7.35%

Wangjing Hospital affiliated to China Academy of Chinese Medical Science	93 (58/35)	2.63%

Xiyuan Hospital affiliated to China Academy of Chinese Medical Science	462 (304/158)	13.06%

China-Japan Friendship Hospital	632 (425/207)	17.87%

Beijing Hospital of Integrated Traditional Chinese with Western Medicine	124 (80/44)	3.51%

Anzhen Hospital affiliated to Capital University of Medical Sciences	616 (422/194)	17.42%


Cluster of Life Sciences	BMBS - Biomedicine and Molecular BiosciencesFA - Food and AgricultureFPS - Forests, their Products and Services

Cluster of Natural Sciences	CMST - Chemistry and Molecular Sciences and TechnologiesESSEM - Earth System Science and Environmental ManagementMPNS - Materials, Physical and Nanosciences

Cluster of Science and Society	ISCH - Individuals, Societies, Cultures and HealthICT - Information and Communication TechnologiesTUD - Transport and Urban Development

Trans Domain area (not a separate Domain currently) – allows for multidisciplinary proposals which cannot be submitted to a single Domain.


Factor	Factor level	Frequency (n)	Percentage	Chi-square	df	Significance

Habitat stability	Permanent	214	63.13

	Temporary	125	36.87	22.317	1	0.000

Habitat origin	Man-made	326	96.17

	Natural	13	3.83	0.873	1	0.350

Water origin	Surface run-off	279	82.30

	Underground	60	17.70	5.254	1	0.022

Habitat size	<10	45	13.27

	>100	50	14.75

	10 - 100	244	71.98	9.822	2	0.007

Water movement	No	301	88.79

	Yes	38	11.21	0.768	1	0.381

Vegetation	Absent	149	43.95

	Present	190	56.05	11.547	1	0.001


Demographic characteristics	Value

Age in years, mean (range)	55.9 (42 to 79)

Race, n (%)

White	4 (50)

African heritage	2 (25)

Asian - Japanese/East Asian/Southeast Asian heritage	1 (13)

Asian - Central/South Asian heritage	1 (13)

Baseline ECOG performance status, n (%)

0	6 (77)

2	2 (25)

Time since diagnosis (years), median (range)	4.5 (1 to 9)


Trial	Hb (g/L)	Ferritin (μg/L)	TSAT (%)	BM iron

Auerbach 2004 [26]	≤105	≤200	≤19*	 ND

Auerbach 2010 [31]	≤100	≥10	≥15	 ND

Bastit et al. [29]	<110	10–800	≥15	 ND

Hedenus et al. [28]	90–110	<800	—	 +

Henry et al. [27]	<110	100–900	15–35	 ND

Pedrazzoli et al. [30]	<110	100–800	20–40	 ND

Steensma et al. [32]	<110	≥20	<60	 ND


	Healthy volunteers	ObT2D	HV/ObT2D

(n = 19)	(n = 20)	p value

Intra-myocardium dixon fat fraction (%)	7.9 ± 3.7	6.0 ± 1.5

Dixon 3D epicardial fat volume (mL)	176.4 ± 68.6	273.8 ± 64.0	***

Indexed dixon 3D epicardial fat volume (mL/m2)	89.7 ± 25.2	123.6 ± 23.4	***

Dixon 3D epicardial fat fraction (%)	21.0 ± 4.0	28.4 ± 5.5	***


Stage 1: selection of study sites

Region	Country	Estimated no. ART clinics (yr. of assessment)	Estimated no. adult ART enrollees at ART clinics	No. eligible clinics*	Estimated no. study-eligible adult ART enrollees at eligible clinics	Site sampling technique	No. clinics selected

Southern Africa	Mozambique	379 (2014)	582,000	254	446,379	Census	254

Namibia	213 (2014)	165,468	213	165,468	Census	213

Swaziland	31 (2009)	50,767	31	50,767	PPS	16

Zimbabwe	104 (2008)	103,806	70	93,811	PPS	40

Zambia	322 (2007)	65,383	129	58,845	Purposive	6

East Africa	Tanzania	210 (2007)	41,920	85	37,728	Purposive	6

Uganda	286 (2007)	45,946	114	41,351	Purposive	6

West Africa	Nigeria††	178 (2009)	168,335	139	167,438	PPS	35

Caribbean	Haiti	200 (2015)	65,000	191	60,705	Census	191

Southeast Asia	Vietnam	173 (2009)	28,090	120	25,000	PPS	30

Total	—	2,096	1,316,715	1,346	1,147,492	—	797

Stage 2: selection of study patients

Region	Country	Age-eligibility criteria (age at ART initiation) (yrs)	ART enrollment years covered by analysis	Patient sampling technique at selected clinics	Planned sample size*	No. eligible medical recordsanalyzed	Date of data collection

Southern Africa	Mozambique	≥15	2004–2013	Census	446,379	446,379	Dec 2014

Namibia	≥15	2004–2012	Census	165,468	165,468	Dec 2013

Swaziland	≥15	2004–2010	SRS	2,500	2,510	Nov 2011–Feb 2012

Zimbabwe	≥15	2007–2009	SRS	4,000	3,896†	Jan–Jun 2010

Zambia	≥18	2004–2009	SRS	1,500	1,214§	Apr–Jul 2010

East Africa	Tanzania	≥18	2004–2009	SRS	1,500	1,421¶	Apr–Jul 2010

Uganda	≥18	2004–2009	SRS	1,500	1,466**	Apr–Jul 2010

West Africa	Nigeria††	≥15	2004–2011	SRS	3,500	3,496	Dec 2012–Aug 2013

Caribbean	Haiti	≥15	2004–2015	Census	60,705	60,705	Jun 2016

Southeast Asia	Vietnam	≥15	2005–2009	SRS	7,587	7,583§§	Jan–Jun 2010

Total	—	—	—	—	694,639	694,138	—


CT technique description	Injection activity (MBq)	Effective dose (mSv)	Effective dose per unit activity (mSv/MBq)

	Male	Female	Male	Female	Male	Female

Standard CT	455 ± 30	450 ± 26	8.1 ± 1.2	10.1 ± 1.4	0.018 ± 0.002	0.022 ± 0.002

Diagnostic CT	455 ± 25	454 ± 51	8.1 ± 0.8	9.9 ± 1.6	0.018 ± 0.002	0.022 ± 0.003


Gene Ontologya	DAVIDb

Biological process

 Cell adhesion (GO:0007155)	0.0000148

 Cell communication	0.000632

G-protein signaling, coupled to cyclic nucleotide second messenger	0.001940c

 System development (GO:0048731)	0.000000016

Central nervous system development	0.000293c

 Organ development (GO:0048513)	0.000017

Cellular compartment

 Integral to membrane (GO:0016021)	0.0000018

 Integral to plasma membrane (GO:0005887)	0.000000026

 Dystrophin-associated glycoprotein complex	0.002081c

Sarcoglycan complex	0.004398c

Molecular function

 Signal transducer activity (GO:0004871)	0.0000025

 Transmembrane receptor activity (GO:0004888)	0.0000274

Transmembrane receptor protein phosphatase activity	0.003811c

Amine receptor activity	0.004557c

Hematopoietin/interferon-class (D200-domain) cytokine receptor activity	0.001526c

 Phosphoinositide binding	0.000737c

GPI anchor binding	0.003257c

 Calcium-release channel activity	0.004102c

 Delayed rectifier potassium channel activity	0.001212c

Enriched KEGG pathways	PEb

 Cell adhesion molecules (CAMs)	0.00000036

 Neuroactive ligand-receptor interaction	0.000542

 Allograft rejection	0.001545

 Type I diabetes mellitus	0.003487


Outcome and instrument	Method	Data collection time

T0	T1	T2

Perceived health

SF-36	Interview caregiver or mailed questionnaire	x	x	x

Objective burden

Short version iBMG	Interview caregiver or mailed questionnaire	x	x	x

instrument objective burden informal care

Subjective burden

Carer-Qol	Interview caregiver or mailed questionnaire	x	x	x

SRB	Interview caregiver or mailed questionnaire	x	x	x

CSI+	Interview caregiver or mailed questionnaire	x	 	x

Perseverance time	Interview caregiver or mailed questionnaire	x	 	x

ASIS	Interview caregiver or mailed questionnaire	x	 	x

Quality of life

SF-36	Interview caregiver or mailed questionnaire	x	x	x

Cantril’s self-anchoring ladder	Interview caregiver or mailed questionnaire	x	x	x

Use of community services

Self-reported	Interview caregiver or mailed questionnaire	x	x	x

CSAI	Interview caregiver or mailed questionnaire	x	 	x


Strategy	Treatment	Genomic Profile	Phase	N	ORR (%)	PFS (M)	OS (M)	Clinical Development	Reference

BRAF monotherapy	Vemurafenib	BRAFmut	I/II	21	5	2.1	7.7	Complete	NCT00405587 [93]

BRAF monotherapy	Vemurafenib	BRAFmut	II	10	0	4.5	9.3	Complete	NCT01524978 [94]

BRAF + MEK	Dabrafenib + Trametinib	BRAFmut	I/II	43	12	3.5	(−)	Complete	NCT01726738 [88]

BRAF + EGFR	Vemurafenib + Cetuximab	BRAFmut	II	27	4	3.7	7.1	Complete	NCT01524978 [94]

BRAF + EGFR	Vemurafenib + Panitumumab	BRAFmut	Pilot	15	13	3.2	7.6	Complete	NCT01791309 [89]

BRAF + EGFR	Encorafenib + Cetuximab	BRAFmut	II	50	22	4.2	12.4	Ongoing	NCT01719380 [90]

BRAF + EGFR	Dabrafenib + Panitumumab	BRAFmut	I/II	20	10	3.4	(−)	Ongoing	NCT01750918 [85]

BRAF + EGFR	BMS-908662 + Cetuximab	Kras mut or BRAF mut	I/II	17 *	(−)	(−)	(−)	Ongoing	NCT01086267

BRAF + EGFR + CT	Vemurafenib + Cetuximab + irinotecan	BRAFmut	I	12	50	(−)	(−)	Ongoing	NCT01787500

BRAF + EGFR + CT	Cetuximab + irinotecan ± Vemurafenib	BRAFmut	II (RCT)	78 *	(−)	(−)	(−)	Ongoing	NCT02164916

BRAF + EGFR + MEK	Dabrafenib + Panitumumab + Trametinib	BRAFmut	I/II	83	18	(−)	(−)	Ongoing	NCT01750918 [85]

BRAF + EGFR ± MEK	Encorafenib + Cetuximab ± Binimetinib	None	III	645 *	(−)	(−)	(−)	Ongoing	NCT02928224

BRAF + EGFR + PI3K	Encorafenib + Cetuximab + Alpelisib	BRAFmut	II	52	27	5.4	13.1	Ongoing	NCT01719380 [90]

MEK + CT	Selumetinib + irinotecan	Kras mut or BRAF mut	II	32	9	(−)	(−)	Complete	NCT01116271 [95]

MEK + EGFR	Binimetinib + Panitumumab	RAS wt or RAS mut	I/II	90 *	(−)	(−)	(−)	Ongoing	NCT01927341

MEK + EGFR	Panitumumab + Trametinib	BRAFmut	I/II	31	0	2.8		Ongoing	NCT01750918 [85]

MEK + EGFR	Trametinib + Panitumumab	KRAS BRAF wt	II	26 *	(−)	(−)	(−)	Ongoing	NCT02399943

MET + EGFR + CT	Cetuximab + irinotecan ± Tivantinib	KRAS wt	I/II (RCT)	60	45	8.3	19.8	Complete	NCT01075048 [96]

MEK + AKT	Selumetinib + MK-2206	KRAS wt or KRAS mut	II	21 *	(−)	(−)	(−)	Ongoing	NCT01333475


Dose level	N	Radiation therapy dose (Gy)	Dose delay due to AE

Level 1	3	62	62a	64	1 (3 days)

Level 2	6	64	60	62	0

	64	62	60

Level 3	6	60	64	62	1 (7 days)

	64	60b	62


Socio -demographic Characteristic	Number	%

Age (in years)

 15–34	109	25.6

 25–34	166	39.1

 35–44	150	35.3

Ethnicity

 Sinhalese	256	60.2

 Tamils	83	19.5

 Muslims	80	18.9

 Burgher & others	6	1.4

Religion

 Buddhism	244	57.4

 Hindu	72	16.9

 Islam	78	18.4

 Christianity	31	7.3

Current marital Status

 Currently Married	286	67.3

 Never Married	98	23.1

 Widowed	24	5.6

 Divorced/ Separated	17	4.0

Highest level of Education

 Never went to school	48	11.3

 Primary education	197	46.3

 Secondary education or higher	180	42.4

Daily family income (in USD)

 Less than 2.4 USD (poor income)	73	17.2

 2.5–12 USD (low income)	348	81.9

 More than 12 USD (middle income)	4	0.9

Employment status

 Employed	224	52.7

 Unemployed	201	47.3

Employment Category (n = 224)

 Professionals	14	6.3

 Clerical and sales workers	34	15.1

 Elementary occupations	113	50.5

 Others	63	28.1

Social status

 High social status	106	24.9

 Low social status	319	75.1


Assay		Primer Sequence 5’-3’

<underline>Pyrosequencing</underline>

Assay 1 (20 CpGs)	Forward	GGATGTGGGGATTTTTTTTTTTTAGTATAG

	Reverse	Biotin-ACTTCAACCCCTCCCCCAAAA

	Sequencing 	TTTTTTAGTATAGTAAAGTTGGT

Assay 2 (12 CpGs) 	Forward	TTTCGGGTTTTATAGTTTTTGTATTTAGGT

	Reverse	Biotin-ACTCCCGCAACTCAATAAACTCAAACTC

	Sequencing 	TTTAGTAGTTTAGTTTGGATTTTGG

MOAP1 	Forward	GAGTGTTAGTTAGAGTTTAGGGGAGTTT

	Reverse	Biotin-CTCACCCCTCCCAACCCT

	Sequencing 	AGGGGAGTTTGTTTT

<underline>qRT-PCR</underline>

GAPDH 	Forward	CATGACAACTTTGGTATCGTG

	Reverse	GTGTCGCTGTTGAAGTCAGA

RASSF1a	Forward	CCTCTGTGGCGACTTCATCTG

	Reverse	CAACAGTCCAGGCAGACGAG

MOAP-1	Forward	CTCAATTGCTCCTCTCTGTACC

	Reverse	CATGACAACTTTGGTATCGTG

RASSF1c	Forward	GCTACTGCAGCCAAGAGGAC

	Reverse	AGGTGTCTCCCACTCCACAG

PPIA	Forward	GCCGAGGAAAACCGTGTACT

	Reverse	TGTCTGCAAACAGCTCAAAGG


Riparian metric	Mean annual rainfall	Mean annual temperature	Bank height	Proportion of clay

Estimate	SE	Estimate	SE	Estimate	SE	Estimate	SE

SPECIES RICHNESS	0.0347***	0.009	0.0238**	0.0085	−0.0178	0.009

ABUNDANCE	12.933**	3.824

NATIVE REGEN	13.904***	3.314	6.708**	3.824

BASAL AREA	0.631*	0.299

SPECIES RICHNESS NS	0.047***	0.012

NATIVE REGEN NS	10.207*	4.020

BASAL AREA NS							0.199**	0.068


 	O. scapulalis	O. nubilalis

Raw short sequence number	322,504	307,622

Number after filtering	287,429	272,490

Mean read length (bp)	352	356

Number of singletons	85,070	87,110

Number of assembled reads	145,588	130,897

Assembled transcriptome (Mbp)	10.35	9.52

Reads/bp	9.8	10.2

Number of unigenes	8,892	8,656

Number of transcripts (including alternative transcripts)	11,231	10,773

Transcript mean length (bp)	922	883

Transcript median length (bp)	693	685

Transcript N50 length (bp)	1,036	991

Mean exon count per transcript	1.54	1.49

Mean exon* length (bp)	604	605

Median exon length (bp)	500	495


Study [reference]: countries	Population	n	Efficacy	Lower bound of 95% CI	Adherencea

Partners PrEP [8]: Kenya, Uganda	Heterosexual couples	4758	67% TDF; 75% TDF/FTC	44% TDF; 55% TDF/FTC	82%

TDF2 Study [9]: Botswana	Young men and women	1219	62% TDF/FTC	21.5%	80%

Bangkok TDF [12]: Thailand	IVDU	2413	49% TDF	9.6%	67%

iPrEx [7]: S. America, SA, Thailand, USA	MSM	2499	44% TDF/FTC	15%	51%

FEM-PrEP [10]: Kenya, SA, Tanzania	Young women	2120	6% TDF/FTC	−52%	37%

VOICE [11]: South Africa, Uganda, Zimbabwe	Young women	5029	−49% TDF; - 4% TDF/FTC	−130% TDF; −50% TDF/FTC	30%


	PANSS positive subscale score	PANSS negative subscale score	PANSS general psychopathology subscale score	PANSS total score

Serum S100B level changes	r=0.3P=0.2	r=-0.048P=0.8	r=0.05P=0.8	r=0.06P=0.7

Leptin (microg/ml)	r=-0.3P=0.1	r=-0.023P=0.9	r=-0.2P=0.2	r=-0.3P=0.1


	Run 1	Run 2	Summary

HRM	n	%	n	%	n	%

 Number of samples	120	100.0	20	100.0 (16.7)	120	100.0

 Analysis passed	89	74.2	18	90.0	105	87.5

WT (total)	60	67.4	12	66.7	71	67.6

WT (skewed HRM curve)	3	5.0	2	16.7	4	5.6

Mutant (total)	29	32.6	6	33.3	34	32.4

Mutant (skewed HRM curve)	1	3.4	1	16.7	1	2.9

 Analysis failed	31	25.8	2	10.0

Pyrosequencing	n	%	n	%	n	%

 Number of samples	19	100.0 (15.8)	3	100.0 (2.5)	19	100.0

 Analysis passed	18	94.7	2	66.7	18	94.7

WT	12	66.7	0	0.0	13	72.2

Potential low level mutation	2	11.1	1	50.0	0	0.0

Mutant	4	22.2	1	50.0	5	27.8

 Analysis failed	1	5.3	1	33.3	1

Combined HRM + Pyrosequencing					n	%

 Number of samples					120	100.0

 Number of HRM runs					140	116.7

 Number of pyrosequencing runs					22	18.3

 Analysis passed					119	99.2

 WT					81	68.1

 Mutant					38	31.9

 Analysis failed					1	0.8


URL structure	Get	Post	Delete

/namespace/object_type/	List objects, apply filters	Create new object or make bulk update	Bulk delete

/namespace/object_type/id/	Access single object	Update single object	Delete single object

/namespace/object_type/id/acl/	Get object permissions	Update object permissions	405 Not Supported


		Gender

Female	Male	Total

Need for treatment

 Discussed and confirmeda	17	36	53

 Discussed, not confirmed	0	0	0

 Not mentioned	1	0	1

Danger to self

 Discussed and confirmed	2	2	4

 Discussed, not confirmed	2	5	7

 Not mentioned	14	29	43

Danger to others

 Discussed and confirmed	0	3	3

 Discussed, not confirmed	3	2	5

 Not mentioned	15	31	46

Voluntary care unrealistic

 Discussed and confirmed	5	5	10

 Discussed, not confirmed	0	2	2

 Not mentioned	13	29	42

Substance abuse

 Discussed and confirmed	0	8	8

 Discussed, not confirmed	6	10	16

 Not mentioned	12	18	30


RTI/STI symptomatic currently or within last 3 months	n = 353	%

Sought care for RTI/STI symptoms

 Yes		238	67.4

 No		115	32.6

Time delay until seeking care (days)	(n = 238)

 Mean: 10.2	(range: 2-60)

 < 7		137	57.6

 7-14		55	23.1

 > 15		46	19.3

Source of RTI/STI treatment the last time	(n = 238)

 Drop-in centre		126	52.9

 Public hospital		56	23.5

 Private clinic		29	12.2

 Pharmacy/drugstore		22	9.2

 Herbalist		5	2.1


 	LBD alone (n = 62)	EST plus LBD (n = 69)	P value

Diameter of inflated balloon (mm)	15.9 ± 2.3 (12-20)	16.2 ± 2.5 (12-20)	0.444

Complete stone removal irrespective of whether ML was used, no. (%)	60 (96.8)	66 (95.7)	0.738

Complete stone removal without ML, no. (%)	50 (80.6)	51 (73.9)	0.360


Disease class	Nt	Nur	FIC

Gastrointestinal	17	145	0.88

Respiratory	5	15	0.71

Wound healing	2	3	0.50

Dermatological	1	2	1.00

Kidney problems	2	4	0.66

Blood diseases	4	10	0.66

Cardiovascular	1	3	1.00

Inflammations	1	1	1.00

Hepatic problems	2	5	0.75

General pain	3	6	0.60

Fever	1	3	1.00

Dental	1	3	1.00


Phenotype	n	CaseAverageRelatedness	MeanControlAverageRelatedness	Empiricalp-valueGIF	Empiricalp-valueDistantGIF

CFS	811	3.15	2.31	< 0.001	0.010


 	 	 	Normal PI	Low PI

Restricted growth parameters	Subclass of SGA	N	no (%)	no (%)

Weight, length and OFC	Symmetrical	1	1 (100.0)	0 (0.0)

Weight and length alone	Symmetrical	25	23 (92.0)	2 (8.0)

Weight alone	Asymmetrical	33	20 (60.6)	13 (39.4)


References	Primary outcomes	Secondary outcomes

Song (weak)1[44]	Recalled stocking and sales scores were higher in intervention stores than in control stores.	There was improvement in some specific mediator factors but not in overall mediator factors.

Gittelsohn 2010b (weak) [42]		No changes were shown in most mediator factors between intervention and control stores.

Ayala 2013 (moderate)2[29]	The intervention increased availability of vegetables but not fruit.	Self-efficacy for consuming more fruits decreased.